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General introduction 
 
- Lysosomal storage diseases  
The lysosomal storage diseases (LSDs) are a group of more than 50 inborn 
metabolic disorders. LSDs are caused by mutations in genes encoding 
soluble acidic hydrolases, integral membrane proteins, activator proteins, 
transporter proteins, or nonlysosomal proteins that are necessary for 
lysosomal function. Functional deficiencies in these proteins trigger a 
pathogenetic cascade that leads to intralysosomal accumulation of 
undegraded substrates in multiple tissues and organs. LSDs are traditionally 
classified according to the chemical properties of the accumulated substrate. 
Individually, each of these disorders is rare. However, their cumulative 
prevalence is relatively high when compared with other groups of rare 
diseases, and prevalence is estimated to be approximately 1 in 8,000 live 
births [Fuller M et al, 2006, Parenti et al, 2015 ]. 
LSDs are multisystem diseases and in most instances are highly debilitating, 
shorten patients’ survival, and cause progressive physical and neurological 
handicaps. The clinical consequence of substrate storage in multiple organs 
and systems is the variable association of visceral, ocular, hematological, 
skeletal, and neurological manifestations, and there is partial phenotypic 
overlap among different disorders. Symptoms may emerge at variable ages, 
in some cases starting in utero or becoming evident in late adulthood. In 
general, the diseases progress and evolve over time.  
LSDs are often responsible for physical and neurological disabilities, and they 
have impacts on patients’ health and life expectancy. For all these reasons, 
caring for patients with LSDs requires a multidisciplinary approach. Although 
remarkable progress in treatment has been made in recent years, these 
disorders remain associated with important unmet medical needs and heavy 
burdens in terms of public health and economic costs [Parenti et al, 2015]. 
The past 25 years have been characterized by intensive and continual efforts 
to develop therapies specifically aimed at correcting the metabolic defects of 
these disorders. The approaches developed to treat LSDs are based on 
different strategies, each targeting a specific event in the pathogenetic 
cascade. 
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These approaches include strategies aimed at increasing the residual activity 
of a missing enzyme, as enzyme replacement therapy (ERT) [Brady, 2006], 
hematopoietic stem cell transplantation (HSCT) [Orchard et al, 2007], enzyme 
enhancement therapy (EET) by pharmacological chaperones [Fan, 2008] and 
gene therapy and approaches based on reducing the flux of substrates to 
lysosomes, as substrate reduction therapy (SRT) [Butters et al, 2005]. As 
knowledge has improved about the pathophysiology of lysosomal storage 
diseases, novel targets for therapy have been identified, and innovative 
treatment approaches are being developed. For many LSDs reliable markers 
of disease progression and treatment efficacy would be required.  
 
In this thesis I have studied two models of lysosomal disorders, Pompe 
disease (PD) and Fabry disease (FD). 
  
- Pompe disease 
PD (glycogenosis type II) is a prototype of LSD in which several of these 
problems, related to ERT efficacy, were encountered both in clinical and in 
laboratory studies. PD is an autosomal recessive disorder, with an estimated 
incidence of 1:40,000 live births. Since the first description of PD by the Dutch 
pathologist Johannes C. Pompe in 1932 continuous progress has been made 
in the understanding of its biochemistry and genetics and in the 
characterization of its phenotypic spectrum [Hirschhorn and Reuser, 2001; 
van der Ploeg and Reuser, 2008]. 
PD is a metabolic myopathy caused by mutations of the GAA gene, resulting 
in functional deficiency of the lysosomal hydrolase acid α-glucosidase (GAA, 
acid maltase, E.C.3.2.1.20) [van der PLoeg et al, 2008].  
The GAA gene, localized in 17q25.2-q25.3, consists of 20 exons spread over 
28 kb of genomic sequence and encodes for a protein of 952 amino acids with 
a predicted molecular mass of 110 kDa [Hoefsloot et al, 1990]. The 110 kDa 
GAA protein synthesized in the endoplasmic reticulum is a precursor 
polypeptide, which undergoes N-glycan processing in the Golgi apparatus, 
and is proteolytically processed in the lysosomes into active isoforms of 76 
and 70 kDa, through an intermediate molecular form of 95 kDa [Hoefsloot et 
al, 1990]. 
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The mature enzyme hydrolyzes the alpha-1,4 and 1,6-glycosidic bonds of 
glycogen, releasing glucose units that are then transported across the 
lysosomal membrane by a specific carrier. 
Being GAA deficiency ubiquitous, PD is a multisystemic disease with 
glycogen storage occurring in almost every tissue and cell type. However, 
disease manifestations are predominantly related to muscle involvement and 
heart and skeletal muscle are the major sites of pathology.  
Different mutations of the GAA gene result in a wide phenotypic spectrum, 
with respect to age of onset of manifestations, rate of disease progression 
and variable association of symptoms. The different clinical forms of PD range 
from a devastating classic infantile phenotype, characterized by early onset, 
severe cardiomyopathy and early lethality, to intermediate phenotypes and 
late onset (childhood, juvenile or adult) forms in which cardiac involvement is 
absent or mild [Hirschhorn et al, 2001; Kishnani et al, 2004; , Slonim et al, 
2000]. 
 
- Fabry disease 
Fabry disease (FD, OMIM 301500, ORPHA324) is an X-linked metabolic 
disorder due to mutations in the GLA gene encoding the lysosomal hydrolase 
alpha-galactosidase A (alpha-Gal A, EC 3.2.1.22). Functional deficiency of 
alpha-Gal A results in storage of globotriaosylceramide (Gb3) and related 
neutral glycosphingolipids [Germain, 2010] in vascular endothelial cells, kidney 
cells, cardiomyocytes and neurons.  
Progressive accumulation of globotriaosylceramide and related 
glycosphingolipids (galabiosylceramide) within lysosomes has been shown to 
trigger a cascade of events including cellular death, compromised energy 
metabolism, small vessel injury, channel dysfunction in endothelial cells, 
oxidative stress, impaired autophagosome maturation, tissue ischemia, and 
cardiac and renal tissue fibrosis [Germain, 2010]. This cascade of events 
leads to selective damage of the renal glomerular and tubular epithelial cells, 
the myocardial cells and valvular fibrocytes, neurons of the dorsal root ganglia 
and autonomic nervous system, as well as the endothelial, perithelial, and 
smooth muscle cells of the vascular system. 
The initial signs and symptoms of FD emerge during childhood and 
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adolescence and typically include neuropathic pain crises, angiokeratomas, 
hypohidrosis, and gastrointestinal problems, including diarrhea, constipation, 
abdominal pain, nausea and vomiting. Disease progression in adulthood leads 
to progressive and potentially life-threatening manifestations, including renal 
failure, cardiomyopathy, premature myocardial infarctions, and stroke. Major 
organ involvement typically presents between the age of 20 and 30 years. 
FD is one of the most common lysosomal storage diseases with an estimated 
prevalence of approximately 1 in 100,000 [Fuller et al, 2006; Germain, 2010]. 
However, this prevalence is likely underestimated. An Italian screening 
program in 37,104 male neonates demonstrated an incidence of alpha-Gal A 
deficiency of 1 in 3,100 males and of 1 in 4,600 males with known disease 
mutations [Spada et al, 2006]. Studies in selected populations, such as 
patients with unexplained left ventricular hypertrophy [Nakao et al, 1995; 
Elliott et al, 2011] or with renal failure [Nakao et al, 2003; Tanaka et al, 2005], 
indicate that because signs and symptoms of the disease are in most cases 
non-specific, FD patients are frequently misdiagnosed, and the correct 
diagnosis of FD may be delayed. 
 
In this thesis, for both these disease models I have explored the potential of 
microRNAs (miRNAs) as new tool for understanding of the diseases 
pathophysiology and as new potential biomarkers to follow disease diagnosis, 
progression and follow up of patients. 
 
- MicroRNAs (miRNAs): their role in health and disesase. 
miRNAs are a growing class of small non-coding RNAs (ncRNA) that regulate 
gene expression by targeting messenger RNAs (mRNAs) for translational 
repression or transcript degradation [Bartel et al, 2004]. Mature, biologically-
active miRNAs are ~22 nucleotides in length, and are processed from much 
longer primary transcripts by the RNAse enzymes Drosha and Dicer in the 
nucleus and cytoplasm, respectively [Bartel et al, 2004; Shukla et al, 2011]. 
miRNAs bind to complementary sequences usually located in the 3’ 
untranslated region (UTR) of target genes and regulate post-transcriptionally 
their expression by reducing the stability and translational efficiency of their 
corresponding messenger RNA [Eulalio et al, 2008; Djuranovic et al, 2012; 
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Fabian et al, 2012]. To date, more than 2000 miRNAs have been identified in 
the human genome (miRBase version 19). It is estimated that a single miRNA 
may regulate hundreds of mRNAs and thus, has the potential to greatly 
impact gene expression networks [Bushati et al, 2007; Bartel et al, 2009; 
Pasquinelli et al, 2012]. In humans, deregulation of miRNAs is the hallmark of 
many diseases such as diabetes, neurodegenerative diseases, autoimmune 
conditions, heart failure and cancer among others [Mendell et al, 2012; Croce 
et al, 2009]. Remarkably, mutations in miRNAs have already been shown to 
play a primary pathogenic role in human genetic diseases, including inherited 
deafness [Mencia et al, 2009], keratoconus [Hughes et al, 2011] and skeletal 
abnormalities [de Pontual et al 2011]. 
Circulating miRNAs as disease biomarkers. 
Recently, it has been shown that miRNAs can be exported from cells, loaded 
into lipid-rich vesicles called exosomes and transferred to neighboring or 
distant cells and parts of the body [Kinet et al, 2013]. Indeed, detectable levels 
of miRNAs exist in most extracellular biological fluids including plasma, 
serum, saliva, urine, tears, and breast milk [Kinet et al, 2013]. Circulating 
miRNAs exhibit high stability in serum and plasma samples and can be 
reliably measured [Mitchell et al, 2008]. miRNA signatures in blood appear to 
be tissue- and disease-specific and the miRNA content in circulation is likely 
to provide a read-out of altered pathways in response to disease conditions. 
Pioneering work from the cancer field has shown that miRNA expression 
profiles offer superior resolution compared to mRNA signatures for cancer 
subtype classification and prognosis [reviewed in Allegra et al, 2012]. Indeed, 
circulating miRNAs detected in cell-free serum can distinguish diseased 
individuals from healthy controls for a number of conditions. Considering that 
blood collection is the most common, convenient and non-invasive resource 
of biomarker testing, circulating miRNAs thus have a great potential as 
diagnostic, prognostic and predictive disease biomarkers. Obtaining indirect 
readouts of pathological processes is particularly important for certain 
disorders in which direct access to the affected tissue for molecular analyses 
is invasive.  
There are several examples of alterations in the levels of circulating miRNAs 
associated with a disease condition. In cardiovascular disease, for instance, 
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levels of circulating miR-1, miR-133a and miR-208 can correlate with the 
severity of acute myocardial infarction [Kinet et al, 2013; D’Alessandra et al, 
2010; Cheng et al, 2010; Wang et al, 2010; Kuwabara et al, 2011; Devaux 
2012]. Circulating levels of miR-1, miR-133 and miR-206 have been shown to 
be new and valuable biomarkers for the diagnosis of Duchenne muscular 
dystrophy (DMD) and possibly also for monitoring the outcomes of therapeutic 
interventions in humans [Cacchiarelli et al, 2011]. Distinctive serum miRNA 
profiles have also been described for mouse models of striated muscular 
pathologies [Vignier et al, 2013]. In addition, characteristic circulating miRNA 
profiles have been reported for tissue injury and infection, physiological and 
psychiatric changes (such as pregnancy and bipolar mania [Gilad et al, 2008; 
Rong et al, 2011]. Interestingly, many individual studies claimed that 
circulating miRNA levels returned to baseline levels following treatment such 
as surgical removal of tumours, chemotherapy, acute myocardial infarction 
recovery and other medical treatments, further strengthening the role of 
circulating miRNAs as biomarkers monitoring the effectiveness of treatment 
[Ma et al, 2012; Cacchiarelli et al, 2011].  
The potential of miRNAs as disease biomarkers has been further explored 
with the advancement and accessibility of next generation sequencing (NGS). 
NGS technologies have revolutionized our ability to characterize and quantify 
transcriptomes and provide a more precise measurement of transcript levels 
and their isoforms than microarray technology. State-of-the-art NGS enables 
high-throughput mRNA (RNA-seq) and small RNA analysis (Small RNA-seq) 
through direct sequencing and has a large dynamic range of detection with 
single base resolution that enables accurate quantification of transcript levels. 
Therefore, Small RNA-seq is currently considered the method of choice to 
effectively study miRNA expression. 
miRNAs as therapeutic targets. 
One of the most appealing properties of miRNAs is their ability to concurrently 
target multiple effectors of pathways in the context of a network, thereby 
regulating multiple cellular functions involved in disease development and 
progression. For this reason, targeting miRNAs for therapy is currently of 
great interest. The aberrant expression of a miRNA in disease can be 
modulated as a number of technologies to functionally inhibit or mimic 
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miRNAs already exist. Recent pre-clinical studies from the cancer field 
demonstrated the feasibility and efficacy of delivery of tumour suppressive 
miRNAs through miRNA mimics and inhibition of oncogenic miRNAs through 
delivery of antagomiRs and locked nucleic acid (LNA) molecules [reviewed in 
Ling et al, 2013]. In addition, there is currently an on-going clinical Phase II 
trial (NCT01872936) with miR-122 inhibitor (Miravirsen) for the patients 
infected with chronic hepatitis C virus. These studies highlight the potential of 
miRNAs to be used as drugs or drug targets in the near future. 
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Aim of the thesis 
 
The general aim of the project of my thesis is to identify novel biomarkers for 
the treatment of LSDs, in particular Pompe disease, that may translate into 
improved efficacy of the existing therapies for these disorders. 
Circulating miRNA profile can provide new/valuable biomarkers to monitor 
disease progression and the effects of therapeutic interventions. 
Identification of specific differentially espressed miRNAs (DE-miRNAs) in 
tissues/organs that are primary targets of disease in these LSDs may be 
exploited to develop novel therapeutic approaches and monitor disease 
progression. 
In vitro systems may provide reliable tools and read-outs to evaluate the 
effects of DE-miRNA modulation. 
The analysis of miRNAs in these LSDs represents a way to address 
some of the unmet medical needs: 
- Availability of markers of disease progression; 
- Markers of ERT efficacy; 
- Optimization of costs of therapies (ERT is highly expensive: 300.000-
600.000 eu/year for a single patient);  
- Possible identification of novel therapeutic targets. 
The first aim of the project was focused on the analysis of circulating and 
tissues specific miRNAs in Pompe disease (PD). This study is in the final 
phase with the analysis of a large cohort of patients.   
The second aim of this research project is focused on the analysis of 
circulating and tissue specific miRNAs in Fabry disease (FD). This study was 
performed on the animal model of FD and now is starting on patients.   
Currently, I am also studying the mechanisms underlying the physiophatology 
of Pompe disease and its muscle damage. 
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Chapter 1 
Analysis of circulating and tissue specific microRNAs 
in  Pompe disease. 
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Introduction 
Pompe disease and muscle involvement 
The cascade of events that starting from glycogen storage, the hallmark of 
PD, lead to cell death and muscle atrophy and destruction is still poorly 
understood. For many years, since the identification of lysosomal storage 
diseases, it was assumed that storage “per se” was responsible for cell and 
tissue damage. In PD the rupture of glycogen-filled lysosomes was 
considered the major cause of muscle destruction. Only in the recent years 
studies have been conducted on the molecular and cellular mechanisms 
underlying the extensive disruption of the contractile apparatus in PD and 
suggesting that other factors are likely to concur in causing tissue damage. 
Specifically, these studies addressed a number of questions, such as how 
atrophy and decreased performance contribute to functional insufficiency, and 
what are the cellular events and pathways that are activated by glycogen 
storage and account for morphologic and architectural changes. Elucidating 
these aspects is of great importance, not only for the knowledge of PD 
pathophysiology, but also because these mechanisms are potential targets of 
therapy. 
 
Limited efficacy of ERT on skeletal muscle damage in PD 
The last decade has witnessed extraordinary innovation in the treatment of 
PD. Until 2000 the management of PD patients was exclusively based on 
support treatment. For the strong impact of muscle insufficiency on the 
function of different organs and systems, the management of PD patients, like 
in many others genetic myopathies, requires a multidisciplinary team. 
ERT with recombinant human GAA (rhGAA) is presently the only approved 
pharmacologic treatment to PD [Van den Hout et al, 2000].  
ERT is based on the concept that recombinant lysosomal hydrolases, can be 
administered periodically to patients by an intravenous route. The enzymes 
are internalized by patients’ cells and tissues through the mannose or 
mannose-6-phosphate receptor (MPR) pathways and are ultimately delivered 
to lysosomes, where they are activated and replace the function of the 
defective hydrolases. The presence of mannose-6-phosphate ligands in the 
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enzyme molecules and the integrity of the MPR pathway in the target cells 
and tissues are therefore crucial for the efficacy of this therapeutic approach. 
The results of the published studies showed dramatic improvements of 
cardiac, respiratory and motor function in some patients, whereas in others 
ERT failed to cause significant clinical improvement [Kishnani et al, 2006; van 
Capelle et al, 2008]. This suggests that the clinical outcome in response to 
ERT may be variable, correlating with histological evidence of poor glycogen 
clearance [Thurberg et al, 2006], and that correction of glycogen storage in 
skeletal muscle is particularly challenging. Factors such as age at the start of 
treatment, stage of skeletal muscle damage, antibody responses [Amalfitano 
et al, 2001], insufficient targeting of rhGAA to skeletal muscle and high 
clearance of the enzyme by the liver [Raben et al, 2003] play a role in ERT 
efficacy, although the reasons for the variable responses of different PD 
patients are not completely clear and other factors, such as patients' genotype 
and abnormalities of cell functions, may also be implicated. The limitations of 
ERT, together with the high costs of this type of treatment (as much as 
several hundred thousand US dollars for each patient per year), point to the 
need for improved therapeutic strategies. 
 
How to follow disease course and ERT efficacy? 
A major issue in the monitoring of disease stage and therapeutic efficacy is 
the availability of objective and reliable tests that are not influenced by inter 
and intra-investigator variance. Widely used tests are the 6-minute walking 
test (6MW), tests that explore respiratory function (forced vital capacity, FVC; 
maximum inspiratory pressure, MIP; maximum expiratory pressure, MEP), 
tests exploring muscle function (quantitative muscle testing, MRC; timed 
muscle function tests; Rotterdam Handicap 
Scale, RHS; Walton and Gardner-Medwin, WGM, etc), composite tests (Gait 
Stairs Chair Gower, GSCG), and tests evaluating limitations in physical 
activities and social participation (Rasch-designed Pompe-specific Activity 
scale, R-Pact). Although several of these tests have been validated for PD 
[Angelini et al, 2012; van der Beek et al, 2013], some of them some are 
specific for subsets of patients, require specific medical skills and 
collaboration of patients. Key factors in the evaluation of these tests are their 
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clinical relevance and the minimal clinically important difference that for some 
of these tests need to be further established [Lachman and Schoser, 2013]. 
Biochemical or imaging-based tests include the evaluation of the glucose 
tetrasaccharide (GLC4) [Young et al, 2009] in plasma and urine, muscle 
ultrasound [Vill et al, 2014], muscle NMR [Mercuri et al, 2002]. 
Also in these cases, however, the clinical relevance of the tests needs further 
assessment. Serial muscle biopsies do not appear to be a feasible approach 
to evaluate ERT efficacy as they require invasive procedures. 
The availability of reliable tests appears even more important for the 
development of guidelines for the monitoring of patients, for ERT inclusion 
and exclusion criteria that are currently being identified in many countries 
[such as UK, and other European countries]. 
A set of reliable clinical and biochemical tests may also prove to be useful in 
optimizing ERT, and may in principle translate into economical benefits. They 
may also be precious tools in evaluating the efficacy of novel treatments or 
treatment protocols in comparison with existing therapies needs to be 
assessed.
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Objectives 
 
The scope of the project is to identify miRNAs that may serve as markers of 
disease progression and of efficacy of therapies, and to obtain information on 
the pathophysiology of PD. The availability of objective indicators, in 
combination with clinical evaluation, has clinical relevance and may help 
address important issues in the treatment and monitoring of PD patients. 
 
The main aim of the project is to identify, by means of Next-Generation 
Sequencing (NGS)-based approaches, miRNAs acting as biomarkers in PD 
that may be translated into clinical relevant instruments enabling a more 
effective clinical management of patients. This effort could generate reliable 
diagnostic tools for PD that could be used to monitor the efficacy of ERT and 
provide information to optimize therapeutic interventions. Besides their value 
in identifying miRNA biomarkers, the generated data could provide insights 
into the complex mechanisms involved in the pathophysiology of PD, and into 
the functional role of miRNAs in the pathogenesis of the disease, possibly 
leading to the identification of new potential therapeutic targets. 
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Objective 1: Screening of differentially expressed miRNAs in the mouse 
model of PD  
 
miRNAs expression profiles were analyzed by next generation sequencing 
(NGS) in target tissue/organs and plasma samples from the mouse model of 
PD in comparison to wild-type animals and at different time-points that were 
representative of different stages of disease progression. 
The analysis was performed in tissues that were most relevant for the disease 
(heart and gastrocnemius) and in plasma from PD mice and age-matched 
wild-type mice. The tissues were collected at different time-points that 
correspond to different stages of disease progression and severity.  
This analysis had the potential to identify circulating differentially expressed 
miRNAs (DE-miRNAs) that could be used as diagnostic biomarkers for PD and 
tissue specific DE-miRNAs that could be targeted as new therapeutic targets. 
 
Results 
We have analyzed miRNA profiles in plasma and tissues from PD mice with 
the aim to identify “disease-specific” miRNAs for PD. To have a general view 
of the overall detected and DE-miRNAs in the examined tissues, we 
performed the analysis by a NGS-by-synthesis approach, that allows the 
detection of even small differences among samples, and enables the 
identification of non-annotated miRNAs. NGS screening in the PD mouse 
model was performed at 3 and 9 months (two stages of disease progression). 
Plasma and tissues were collected and total RNA was extracted by a 
procedure preserving small RNAs fraction. After small-RNA seq experiment, 
bioinformatics analysis was done to assess reliability and statistical relevance 
of data (FIGURE 1). 
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FIGURE 1 
 
 
The analysis showed one DE-miRNA in plasma at time point of 9 months with 
statistical significance (FDR<0.05). In tissues we found 219 DE-miRNAs in 
muscle (gastrocnemius), and 35 DE-miRNAs in heart. In total, 104 miRNAs 
were differentially expressed at 3 months, 108 at 9 months; 42 were 
differentially expressed at both ages (FIGURE 2).  
 
FIGURE 2 
 
 
 
The NGS analysis generated a list of differentially expressed miRNAs in 
tissues representing the primary target organs of PD. This may represent a 
valuable framework to better understand the abnormalities of cellular 
pathways triggered by storage and associated with the pathogenesis of PD, 
and to identify candidates for therapeutic intervention. In the heatmaps 
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(FIGURE 3) are shown all the heart- and muscle-specific DE-miRNAs that we 
found by NGS. The colours show the levels of alteration of each DE-miRNA 
(in green downregulated miRNAs, in red upregulated miRNAs); the brillance 
of colours is proportionally to the grade of alteration. 
 
 
 
FIGURE 3 
 
 
 
 
Objective 2: Assessment of diagnostic and/or predictive value of 
circulating DE-miRNA and tissues specific DE-miRNAs in the mouse 
model of PD by RealTime PCR (qRT-PCR) 
 
2.1) miR-486 was differentially expressed in plasma of PD mice in comparison 
to wt mice at 9 months of age, with a highly significant FDR (<0.05). 
miR-486 is already known because of its involvement in relevant processes 
for PD. miR-486 is a muscle enriched microRNA, is transcribed within the 
ANK1 gene (a small skeletal muscle-specific protein associated with the 
sarcoplasmic reticulum of skeletal muscle myofibers) [Zhou et al, 1997; 
Gallagher et al, 1998] 
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Its validated targets are important genes (Pax7, Foxo1, Pten) involved in 
pathways as myogenesis and atrophy, that are known to be altered in PD. 
The expression of miR-486 is significantly reduced in dystrophin-deficient 
skeletal muscle; moreover, this miRNA is essential for normal myoblast 
fusion, cellular kinetics and viability and regulates a variety of PTEN/AKT 
signaling components in skeletal muscle [Alexander et al. 2011] 
The miRNA expression data in plasma were validated by performing qRT-
PCR for miR-486 in PD mice at different time points. 
 
2.2) The results obtained obtained by NGS with some tissue-specific DE-
miRNAs were also validated by performing qRT-PCR. These miRNAs were 
selected because of their highly significant FDR (< 0.05) or fold change, or 
due to their involvement in relevant processes for PD. 
Some of these DE-miRNAs are already known to modulate the expression of 
genes involved in pathways such as autophagy, muscle regeneration, 
inflammation that may be relevant for PD pathophysiology. Some of them are 
known to modulate the expression of genes involved in more than one of 
these pathways. 
 
Results 
 
2.1) We first analyzed (by qRT-PCR) plasma from the PD mouse model at 
different ages and stages of disease progression; afterwards we moved to the 
study of human samples obtained from patients. We decided to use this 
approach because in the animal model we had a homogeneous situation with 
respect to phenotype,  age of onset and progression of the disease. 
We performed a time course of circulating miR-486 in PD mouse plasma at 
different time points (3, 6,12, 15, 18, months) to monitor the trend of this DE-
miRNA during the course of disease progression (FIGURE 4).   
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FIGURE 4 
 
 
A cohort of 20 mice (10 wt and 10 PD) was followed since the age of 3 
months. Blood samples were taken every three months to monitor miR-486 
trend during disease progression. qRT-PCR data confirmed NGS data in 
plasma, even if they show a large variability among mice belonging to the 
same group. Like by NGS, at 3 months we did not see a substantial difference 
between wt and PD in the levels of circulating miR-486. At 9 months we 
observed a down-regulation of miR-486 in PD mice plasma vs wt, as already 
observed by NGS. The time-course analysis is still in progress at more 
advanced time points (15, 18, 21 months). 
 
2.2) Some of the tissue specific DE-miRNAs have been selected for further 
evaluation and validation, based on the number of reads resulting by NGS 
and on their potential role. Indeed, some of them have already been reported 
in the literature and are known to modulate the expression of genes involved 
in pathways such as autophagy, muscle regeneration, inflammation that may 
be relevant for PD pathophysiology (FIGURE 5A). Some of them are also 
known to be implicated in more than one of these pathways. We firstly 
selected tissue specific DE-miRNAs that were more interesting for our 
pourpose, due to their implication in important pathways for PD, and because  
they are predicted to target relevant genes involved in important processes 
(FIGURE 5B).  
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FIGURE 5 
 
 
Also in this case, before proceeding with further experiments, we validated 
our data by means of q-RT-PCR. 
We analyzed, in muscle (gastrocmenius) of PD mice at 9 months, some of 
DE-miRNAs selected over previously in figure 5b (FIGURE 6). 
 
FIGURE 6 
 
 
q-RT-PCR confirmed the NGS data trend of DE-miRNAs also in tissues. 
Therefore, we decided to adopt this method as gold standard for our future 
miRNA levels evaluation, because it is faster and less expensive, expecially 
when the attention is mainly focused on few miRNAs with respect to those 
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detected by massively parallel sequencing. 
 
Objective 3: Assessment of diagnostic and/or predictive value of 
circulating DE-miRNA in plasma samples from a cohort of PD patients. 
 
Monitoring miR-486 expression in combination with clinical evaluation, is 
clinically relevant for the follow-up of disease progression and therapeutic 
efficacy in PD patients. To this aim we contacted Italian Centers involved in 
the care of PD patients and started a collaborations with them. 
 
Results 
 
We analyzed plasma samples from 19 PD patients followed at DISMET, 
Naples at the Department of Neurology, University of Messina, and at the 
Department of Neurosciences, Federico II University, Naples. (Ten additional 
plasma samples of PD patients followed at Bambino Gesù Hospital, Rome 
and at the Centre for Rare Disease, Udine will be included in the study).  
Plasma was obtained according to standard procedures during periodic 
follow-up admissions to the respective Hospitals. Peripheral blood was 
collected in EDTA and immediately processed, or stored at -80°C. Samples 
from age-matched controls were analyzed for comparison. 
RNA was extracted (as described) and analyzed by qRT-PCR as indicated 
above. miR-486 levels were higher in PD samples compared to controls, both 
in early onset (p<0.05) (FIGURE 7A) and late onset (control samples 
insufficient for statistical analysis) PD patients (FIGURE 7B).  
The overall trend showed that early onset patients had higher levels of 
circulating miR-486 with respect to late onset ones; this could be due either to 
the severity of disease or to a greater degree of atrophy in the infantile form of 
PD. 
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FIGURE 7 
 
 
The broad variation in the plasma levels of different patients may in principle 
be due to a number of different factors. In this respect it should be noticed that 
patient phenotype, age, clinical forms, age of patients, age of onset of the 
disease and age at the start of ERT administration were non-homogeneous.  
We are currently better analyzing our data on PD patients in comparison with 
age-matched wild type controls and we are also correlating our data with 
clinical info of the patients (reported in TABLES 1 - 2). 
Clinical information on the patients was provided by the sending physicians. 
Specifically, information have been requested concerning: 
- age, gender; 
- phenotype and age at the onset of clinical manifestations (infantile classic, 
infantile non-classic, childhood-, juvenile-, adult-onset), age at diagnosis; 
- on/off ERT, age at start of ERT, ERT doses and frequency; 
- present clinical status with particular attention to motor function, respiratory 
function; 
- collection of plasma samples (time elapsed from last ERT infusion). 
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TABLE 1 
 
 
 
TABLE 2 
 
 
Additional information is needed to better understand which aspect of the PD 
is influenced by circulating miR-486 or vice versa. For instance, we are better 
investigating the time of ERT treatment (i.e. age at the start of ERT for each 
patients, how long they have been subject to the treatment, in which phase of 
ERT infusion the blood sampling has been done). 
 
Objective 4: Analysis of the effects of ERT on circulating DE-miRNA in 
PD mouse model and in early onset PD patients 
 
To gather more information on the changes in miR-486 levels in PD we have 
investigated its trend before and after ERT (with recombinant human alpha-
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glucosidase, rh-GAA, Myozyme).This could help understand if there is a 
correlation between GAA levels and circulating miR-486 levels and if some 
variations may be observed after therapy with the recombinant enzyme. The 
analysis has been performed both in the PD mouse model and in a limited 
number of PD patients for which samples pre- and prost-treatment were 
available. 
The results of these experiments could likely provide more information on the 
effects of ERT and on the expression of miRNAs and genes involved in 
pathways that are important for PD pathophysiology. The information obtained 
could be relevant for the treatment of PD patients and could indicate marker(s) 
to follow and optimize ERT in patients (in terms of frequency of infusions, 
doses, etc.).  
 
 
Results 
 
Only for some infantile patients, followed at our department of Pediatrics, we 
had the possibility to obtain blood samples before starting their periodic ERT 
(pre ERT) and the day after ERT infusion (24h post ERT). 
 
 
FIGURE 8 
 
 
 27 
 
As shown in figure 8, all the 3 patients analyzed had up-regulated levels of 
miR-486 before ERT with respect to the mean of control samples. In each of 
these patients the level of miR-486 was lowered at 24 hrs post ERT. Although 
the patients are only 3, in all of them we found the same trend. Although we 
are aware that a wider cohort of patients is required to confer both statistical 
and biological strength to our findings, the observations obtained so far are 
indicative of a functional relationship between PD, ERT response and miR-
486 deregulation.  
 
We have also analyzed PD mice 9 months old, the age in which we found the 
most pronounced alteration of miR-486, even though with opposite trend with 
respect to PD patients. 
Blood sampling of a group of wt control mice and PD mice was performed 
before ERT with recombinant enzyme (Myozyme) injection and 24h hours 
after injection.  
 
FIGURE 9 
 
 
Before Myozyme injection, miR-486 level was down-regulated in PD mice in 
confront to control ones. After 24 hours of Myozyme injection, we found that 
miR-486 level in plasma rises (FIGURE 9). 
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In conclusion, although opposite with respect to patients, we found again a 
statistically relevant de-regulation of the investigated circulating miRNA in PD 
mouse, thus confirming a tight involvement of miR-486 in PD and suggesting 
that multiple factors may be implicated. On the other hand, the inversion of 
miRNA levels after ERT may indicate a rescue of one or more crucial 
pathway(s) targeted by miR-486, determined by the increased enzyme activity 
induced by ERT 
 
 
Materials and methods 
A KO Pompe disease mouse model obtained by insertion of neo into the Gaa 
gene exon 6 Raben et al, [1998] was purchased from Charles River 
Laboratories (Wilmington, MA), and is currently maintained at the Cardarelli 
Hospital's Animal Facility (Naples, Italy). 
Animal studies were performed according to the EU Directive 86/609, 
regarding the protection of animals used for experimental purposes. Every 
procedure on the mice were performed with the aim of ensuring that 
discomfort, distress, pain, and injury would be minimal. Mice were euthanized 
following ketamine xylazine anesthesia. 
Human PD fibroblasts (approximately 30 cell lines) and myoblasts (5 cell 
lines) are already available at the cell bank of the Department of Translational 
Medical Sciences (DISMET), Section of Pediatrics, 
Federico II University, Naples.  
Plasma samples were collected from 17 PD patients followed at DISMET, 
Naples at the Department of Neurology, University of Messina, and at the 
Department of Neurosciences, Federico II University, Naples. Plasma was 
obtained according to standard procedures during periodic follow-up 
admissions to the respective Hospital. Five ml of peripheral blood was 
collected in EDTA and immediately processed, or stored at -80°C. Samples 
from age-matched controls were analyzed for comparison. 
Nine muscle biopsy samples are already available at DISMET (kindly 
provided by Prof. Antonio Toscano, Dept. of Neurology, University of Messina, 
and by Prof. Lucio Santoro, Dept. of Neurosciences, Federico II University, 
Naples). The samples have been obtained for diagnostic purposes and 
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patients have consented to their storage and use for research. 
 
Total RNA extraction preserving miRNA fraction. 
The methodology for extraction and analysis is already established in our 
laboratories.  
Tissue samples were immediately submerged in RNA Stabilization Reagent 
(RNA later; QIAGEN), to stabilize RNA and preserve the gene expression 
profile, and frozen. Total RNA, including small RNAs, was extracted using the 
miRNeasy Kit (Qiagen) following the manufacturer′s instructions. RNA was 
quantified using a NanoDrop ND-8000 spectrophotometer (NanoDrop 
Technologies) and the integrity was evaluated using an RNA 6000 Nano chip 
on a Bioanalyzer (Agilent Technologies). Only samples with an RNA integrity 
number (RIN)>8.0 were used for library preparation.  
 
Small RNA-seq analysis in tissues 
Small RNA libraries were constructed using a Truseq small RNA sample 
preparation kit (Illumina) following the manufacturer′s protocol. Using 
multiplexing, we combined up to 12 samples into a single lane in order to 
obtain sufficient coverage. Equal volumes of the samples that constituted each 
library were pooled together immediately prior to gel purification and the 147-
157 bp products from the pooled indexes were purified from a 6% 
polyacrylamide gel (Invitrogen). Libraries have been quality-checked using a 
DNA 1000 chip on a Bioanalyzer (Agilent Technologies) and quantified using 
the Qubit® 2.0 Fluorometer (Invitrogen).  
 
Small RNA-seq analysis in plasma 
For the analysis of circulating miRNA, we collected plasma from PD mice and 
age-matched wild-type mice by centrifugation of blood in serological tubes. For 
the preparation of plasma, EDTA was used as anticoagulant. Every effort was 
made to limit pre-analytical variation that could affect miRNA quantification. 
For instance, particular attention was given to prevent hemolysis. We 
monitored the levels of the granulocyte-specific miR-223 to assess the extent 
of hemolysis in the collected samples. All downstream processing of plasma 
samples from PD and control sets were conducted simultaneously to minimize 
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batch effect. Prior to RNA extraction, a C. elegans-specific synthetic 
exogenous miRNA (ce-miR-39) was spiked in the samples as control for the 
extraction efficiency. RNA was isolated using the miRNeasy Kit (Qiagen) and 
RT-PCR was performed using miScript System (Qiagen). RNA recovery was 
assessed by comparing the Ct values (obtained with the assay targeting the 
synthetic miRNA) with a standard curve of the synthetic miRNA generated 
independently of the RNA purification procedure. After the assessment of RNA 
recovery, equal amounts based on starting volume (3 l) were used for the 
preparation of small RNA libraries, as previously described for tissue samples. 
 
The sequencing was carried out by the NGS Core Facility at TIGEM, Naples. 
Cluster generation was performed on a Flow Cell v3 (TruSeq SR Cluster Kit 
v3; Illumina) using cBOT and sequencing was performed on the Illumina 
HiSeq1000 platform, according to the manufacturer’s protocol. Each library 
was loaded at a concentration of 10 pM, which we had previously established 
as optimal.  
 
Bioinformatics Analysis 
To identify differentially expressed miRNAs (DE-miRNAs) across samples, the 
raw data were analyzed with the support of the Bioinformatics and Statistics 
Core Facility, TIGEM, Naples. Briefly, the reads were trimmed to remove 
adapter sequences and low quality ends, and reads mapping to contaminating 
sequences (e.g. ribosomal RNA, phIX control) were filtered-out. The filtered 
reads were aligned in parallel both to the mouse genome (mm10) and to 
mouse mature miRNAs (miRBase Release 20) using the CASAVA software 
(Illumina). The number of reads for each miRNA was normalised using 
Trimmed Mean of MS (TMM). The comparative analysis of miRNA levels 
across samples was performed with edgeR, a statistical package based on 
generalized linear models, suitable for multifactorial experiments. 
The potential role, the target genes, and the pathways in which DE-miRNA 
identified by NGS were involved, were studied by bioinformatics tools (Gene 
Ontology, KEGG frequencies) and literature-based analysis (PubMed).  
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Quantitative Real-time Reverse-transcription Polymerase Chain Reaction 
(qRT-PCR) of miRNA and of specific target genes. 
 
Expression of mature miRNAs were assayed using Taqman MicroRNA Assay 
(Applied Biosystems) specific for each miRNA selected for validation. qRT-
PCR was performed by using an Applied Biosystems 7900 Real-time PCR 
System and a TaqMan Universal PCR Master Mix. All the primers for selected 
miRNAs were obtained from the TaqMan miRNA Assays. Samples were run 
in triplicate and small nuclear U6 snRNA and miR-16 (Applied Biosystems) 
were used as internal controls.  
Differences in miRNAs expression, expressed as fold-changes, were 
calculated using the 2-DDCt method. To validate the target genes expression 
data, qRT-PCR was performed for selected target genes of some miRNAs. 
GAPDH, was used as endogenous reference transcript. The levels of selected 
target genes were measured by qRT-PCR using the LightCycler 480 (Roche) 
and specific forward and reverse primers for each target gene. The PCRs with 
cDNA were carried out in a total volume of 20 µl, using 10 µl LightCycler 480 
SYBR Green I Master Mix (Roche) and 400nM specific primers under specific 
conditions that were validated for each of the genes analyzed. All the 
reactions were normalized against murine or human GAPDH. Each sample 
was analyzed in duplicate in two-independent experiments. 
 
In vivo experiments on PD mouse model 
PD ko mice received single injection of Myozyme into the retro-orbital vein 
(doses: 40 mg/kg; 100 mg/kg). The dose of 40 mg/kg corresponds to the dose 
used in human therapy. Plasma and tissue (heart, gastrocnemius) were 
collected 24 hrs or 48 hrs after the infusion and selected miRNA and mRNAs 
were analyzed by qRT-PCR as indicated. The results were compared with 
those obtained in untreated animals. For each group (treated, untreated, 
different time points) 5 animals were tested. 
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Conclusive remarks 
LSDs, including PD, represent a group of invalidating pathologies with a 
strong impact on patients’ life expectancy. 
While remarkable progress in treatment has been made in recent years, the 
molecular mechanisms responsible for the phenotypic manifestations of these 
diseases and the key regulators of the functional pathways involved are still to 
be clarified. Given the increasing relevance conferred to small RNA molecules 
in human disease, also including neuromuscular disorders, we have studied 
the possible role of miRNA deregulation in PD. To globally characterize PD-
specific miRNA expression profiles, we first applied a NGS approach, a new 
generation technology, quantitative and highly sensitive and more reliable if 
compared to hybridization-based methods.  
This represents a versatile method since it can be applied to multiple 
experimental models, including animal ones, where this approach has been 
widely adopted also due to the homogeneous background of this model. 
Moreover, massively parallel sequencing allows, contrary to other high-
throughput technologies, the identification of novel molecules that are still not 
annotated in public databases. 
By performing small RNA sequencing of PD tissues and plasma samples 
isolated from PD mice, we identified several DE-miRNAs in tissues and one 
DE-miRNA in plasma, with respect to healthy mice. 
This finding is somehow expected, particularly because of the known 
difficulties in miRNA purification from plasma, where these molecules are less 
stable and more subjected to degradation by RNAses compared to tissue 
samples. On the other hand, it results really challenging to observe reliable 
differences in plasma, since the identified factors are the results of multiple 
body parameters (Functions?) in a given moment. 
Some of DE-miRNAs have already been reported in the literature and are 
known to modulate the expression of genes involved in pathways such as 
autophagy, muscle regeneration, inflammation, atrophy, that are relevant for 
PD pathophysiology. These results confirm the accuracy of the approach. 
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In plasma we found just one DE-miRNA, but with a great impact for its 
involvement in atrophy and myogenesys, crucial pathways for PD. In early 
onset patients we found more pronounced abnormalities of mi-486 levels, 
likely correlated with disease progression and severity. It is reasonable to 
speculate that miR486 is potentially useful as a biomarker, that may be 
monitored by using non-invasive approaches (blood sampling). 
 
Our results are promising but there is a need for further evaluation in other 
samples. To this end international collaborations and multicenter coordinated 
actions have already been established. 
Specifically, some relevant requests have been made to collaborating centres 
concerning higher number of plasma samples (PD patients and healty 
controls). We are doing an accurate study of correlation with clinical 
information of patients concerning: 
- age, gender; 
- phenotype and age at the onset of clinical manifestations, age at diagnosis; 
- on/off ERT, age at start of ERT, ERT doses and frequency; 
- present clinical status with particular attention to motor function, respiratory 
function; 
- collection of plasma samples (time elapsed from last ERT infusion). 
A circulating miRNA that is differentially expressed in the mouse model of PD 
has already been identified at the time point 9 months, but the NGS analysis 
at different time points, particularly in more advanced stages of disease (14 
months and 21 months) is in progress. This might result in the identification of 
additional circulating DE-miRNAs.  
As previously stated the availability of biochemical indicators, in combination 
with clinical evaluation, has clinical relevance for the monitoring of disease 
progression and therapeutic efficacy in PD patients. 
 
Ongoing objectives 
 
Objective 1: NGS analysis at more advanced stages of disease (14 
months and 21 months) 
 
Objective 2: Assessment of diagnostic and/or predictive value of tissue 
 34 
specific DE-miRNAs and specific target genes in PD mouse model 
muscle and in PD patients muscle biopsies. 
  
Objective 3: Analysis of selected DE-miRNAs in mouse- and patient-
derived cells (mouse fibroblasts and myoblasts, patients fibroblasts and 
myoblasts, patients) in vitro. Cultured cells may represent a valuable 
tool to study in vitro the effects of ERT, on miRNA profiling and on 
specific pathways.  
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Chapter 2 
Analysis of circulating and tissue specific microRNAs 
in  Fabry disease. 
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Introduction 
Because many manifestations of the disease are highly debilitating, FD 
imposes a heavy burden on public health, in terms of economical 
investments and need for assistance to patients and their families [Wyatt 
et al, 2012]. The treatment of morbidity associated with FD often 
requires invasive procedures (e.g. dialysis). Some FD manifestations, 
such as stroke, myocardial infarction, may result in physical handicap. 
 
Therapies for Fabry disease 
 Until the beginning of the 2000s the management of FD patients 
was exclusively based on supportive therapies. In 2001, enzyme 
replacement therapy (ERT) with recombinant human alpha-
galactosidase A (rh-alpha-Gal A) was introduced to treat FD [Eng et al, 
2001; Schiffmann et al, 2001]. Two recombinant rh-alpha-Gal A 
preparations are presently approved in Europe for ERT, agalsidase 
alpha (Replagal, Shire), and agalsidase beta (Fabrazyme, Genzyme 
Co). ERT has been shown to promote substrate clearance from vascular 
endothelia and clinical improvement or stabilization of patients [Metha et 
al, 2009; Pisani et al, 2012].  
 In recent years pharmacological chaperone therapy has been 
proposed as an alternative or complementary approach to treat FD [Fan 
et al, 1999] and other lysosomal storage diseases [Parenti el al, 2009]. 
This approach is based on the use of active site-directed ligands (so 
called “chaperones”) that can provide protection against misfolding and 
prevent the degradation of mutated proteins with altered conformations. 
Chaperones have also been shown to act synergistically with ERT in FD 
[Porto et al, 2009; Porto et al, 2012; Pisani et al, 2012; Benjamin et al, 
2012].  
 Other genetic therapies are being considered for the treatment of 
Fabry disease, such as substrate reduction therapy, GLA promoter 
activation, protein homeostasis regulation, next generation ERT, and 
gene therapy. 
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 Open questions and unmet medical needs  
Despite extraordinary progress in the treatment of FD, mainly achieved 
with the introduction of ERT, several issues remain to be addressed and 
unmet medical needs remain associated with this disorder. 
1. Clinical efficacy of ERT. There is some evidence that substrate 
clearance by ERT in specific cell types and tissues is less efficient than 
in other cells. Recent meta-analyses indicated that, while significant 
clinical benefits of ERT have been obtained in some patients (mainly at 
an early phase of the disease), data that support the long-term clinical 
benefits of ERT are less solid [Schaefer et al, 2009; Lidove et al, 2010; 
Rombach et al, 2013]. Although evidence has been provided for an 
association between time on ERT and a decrease in left ventricular 
mass index and increase in the glomerular filtration rate in adults after 
adjustment for age, the magnitude of the differences is small [Wyatt et 
al, 2012]. The effect of treatment on glomerular filtration rate appears to 
plateau after 5 or 6 years on treatment. In some patients long term ERT 
does not prevent disease progression. Although the overall risk of 
developing complications declines with increasing treatment duration, in 
patients with advanced FD a significant risk may persist despite ERT  
[Weidemann et al, 2013]. 
2. When to start treatment? Which patients to treat? Recommendations 
for ERT in patients with FD have been published, and national guidelines 
exist in some countries. These guidelines, however, remain a matter of 
debate particularly when considering indications to start treatment in 
heterozygous female and children, and the appropriate time to start 
therapy in adult males in order to prevent irreversible organ damage. A 
Consensus Conference on FD nephropathy suggests that ERT should 
start at the onset of symptoms in women and at 7–10 years of age in 
asymptomatic boys [Lidove et al, 2007]. Data from the FD outcome 
survey (FOS) on the basis of clinical results of ERT and of its adverse 
effects, suggest that in asymptomatic children a close clinical 
surveillance should be performed, mostly in patients with a family history 
of early disease progression. 
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3. How to follow disease course and ERT efficacy? The efficacy of ERT 
is commonly followed on the basis of clinical and functional measures 
(progression of cardiac, renal or cerebral disease, glomerular filtration 
rate, pain). Biochemical markers that may assist with treatment 
monitoring include globotriaosylceramide and lysoglobotriaosylceramide 
measured in plasma and urine, and anti-agalsidase antibodies. 
However, substrate levels can be difficult to correlate with organ 
involvement or long-term disease progression in females and individuals 
not affected by the classic form of FD [Germain, 2010]. Current efforts 
are directed towards the identification of additional biochemical markers 
by metabolomic approaches [Dupont et al, 2012; Manwaring et al, 2013; 
Lavoie et al, 2013]. 
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Objective 
  
 The second aim of my thesis is focused on the identification, by 
means of Next-Generation Sequencing (NGS)-based approaches, 
microRNAs (miRNAs) acting as biomarkers in FD that could be 
translated into clinical relevant instruments enabling a more effective 
clinical management of patients.  
 This effort could generate reliable diagnostic tools for FD that 
could be used to monitor the efficacy of ERT and provide information to 
optimize therapeutic interventions.  
 Besides their value in identifying miRNA biomarkers, the 
generated data could provide insights into the complex mechanisms 
involved in the pathophysiology of FD, and into the functional role of 
miRNAs in the pathogenesis of the disease, possibly leading to the 
identification of potential therapeutic targets. 
 The analysis of miRNAs in the animal model of FD represents a 
way to address some of the unmet medical needs (e.g. reliable 
biomarkers, need for new therapeutic targets) and provide a better 
understanding of the disease pathophysiology. 
 The circulating miRNA profile can provide new and valuable 
biomarkers to monitor the clinical course of patients, including the early 
stages of the disease, and the outcomes of therapeutic interventions.  
 In addition, the differential expression of FD-specific miRNAs in 
the tissues/organs that are primarily targeted in the course of the 
disease could be used as a point of intervention for novel therapeutic 
approaches.  
 40 
Objective 1: Screening of differentially expressed miRNAs in the mouse 
model of Fabry disease.  
 
 
miRNAs expression profiles were analyzed by next generation sequencing 
(NGS) in target tissue/organs and plasma samples from the mouse model of 
FD in comparison to wild-type animals and at one time-points that were 
representative of different stages of disease progression. 
The analysis was performed in tissues that were most relevant for the disease 
(heart and kydney) and in plasma from FD mice and age-matched wild-type 
mice.  
This analysis had the potential to identify circulating differentially expressed 
miRNAs (DE-miRNAs) that can be used as diagnostic biomarkers for FD.  
 
Results 
As done for Pompe disease, we have performed pilot, proof-of-principle 
experiments of miRNA profiling in plasma and tissue samples from FD and 
wild-type mice with the aim to validate our procedure for the identification of 
“disease-specific” miRNAs in FD. We have studied circulating and tissue 
miRNAs in the animal model of the disease. 
Briefly, we have extracted total RNA from kidney, heart and plasma of the FD 
mouse model at 6 months of age, which represents an early stage of disease 
course. To account for variation in the miRNA contents due to technical and 
biological variability, we harvested our samples from 3 different, age-matched 
mice. Small RNA-Seq libraries were prepared as described previously. 
Overall, by pooling and sequencing 12 samples per lane we could obtain a 
very good coverage for all miRNAs per sample (a total of 373,946,175 raw 
single-end reads per library and a sufficient average of 17,365,764 mappable 
reads per tissue sample and 27,592,835 mappable reads per plasma sample). 
A list of the differentially expressed miRNAs (FDR< 0.05) that were identified 
after comparative analysis is summarized in the table below. 
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FABRY DISEASE mouse model 
HEART 
miRNA ID logFC FDR 
mmu-miR-378a-3p -0.243938198 1.11E-05 
mmu-miR-126a-5p -0.196726546 0.000382356 
mmu-miR-182-5p 1.38554331 0.001662842 
mmu-miR-486-mmu-miR-
3107-5p -0.275621891 0.005104922 
mmu-miR-431-3p -4.635581466 0.059900045 
 
KIDNEY 
miRNA ID logFC FDR 
mmu-miR-1948-3p 6.489832007 0.015984727 
 
PLASMA 
miRNA ID logFC FDR 
mmu-miR-96-5p 4.604963874 0.105568263 
 
 
From these preliminary data we found that 6 miRNAs appear to be 
differentially expressed with statistical significance (FDR< 0.05) in FD mouse 
tissues with respect to age-matched control mice.  
It is possible to speculate that the subset of differentially expressed miRNAs 
might increase with both the progression of disease and age. This has been 
already observed in the mouse model of another lysosomal storage disease 
(Pompe Disease, due to alpha-glucosidase deficiency), investigated at 
different ages by our group (unpublished confidential data). In that case we 
found, particularly in heart, a greater number of differentially expressed 
miRNAs at 9 months, when compared to 3-month-old mice. 
Among all tissue and plasma FD samples investigated, we found four down-
regulated miRNAs, whereas two were up-regulated. In plasma we didn’t find 
circulating miRNAs differentially expressed with FDR <0.05, but we are 
investigating FD mouse model at more advantaged stages and ages of the 
disease.  
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Ongoing objectives 
 
Objective 2: Identification of circulating miRNA profiles in the plasma of 
the mouse model of FD at different stages of disease progression and 
severity. 
 
This specific objective aims at a) identifying miRNAs that are differentially 
expressed in the plasma of the FD mouse model compared to wild-type mice 
and b) establishing a circulating miRNA profile at different stages of disease 
progression. 
To this end, we will harvest plasma from FD mice and age-matched wild-type 
mice by centrifugation of blood in serological tubes.  
This analysis has the potential to identify circulating miRNAs that can be used 
as diagnostic biomarkers for FD even at very early / pre-symptomatic stages of 
the disease. The analysis of FD mice at different time-points of disease 
severity will also enable us to correlate circulating miRNA profiles in the FD 
mouse with clinical parameters of disease manifestation, and with involvement 
of specific organs.   
 
 
Objective 3: Evaluate whether the selected miRNAs are differentially 
expressed also in samples from a cohort of FD patients  
 
This part of the scientific program aims to identify miRNAs that are 
differentially expressed in the plasma from FD patients compared to 5 
volunteer age-matched healthy individuals, and determine to what extent the 
circulating miRNA profiles of FD patients overlap with the ones detected in the 
FD mouse model. 
Towards this end, we will analyze plasma samples obtained from a total of 40 
patients (Table 2) that are followed at the Department of Public Health, 
Section of Nephrology, Federico II University, Naples, Italy.  
In all patients the diagnosis was based on the clinical presentation, alpha-Gal 
A deficiency, and molecular characterization of GLA gene mutations. 
Thirty-two (16 males -16 females) of these patients are currently under ERT, 
whereas 8 are untreated (4 males - 4 females).  
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Patients will be classified according to disease severity and progression by the 
Fabry Outcome Survey-Mainz Severity Score Index (FOS-MSSI) [Whybra et 
al, 2006]. The patients will also be classified for treatment duration. 
 
Table 2 
 
Patient sex Max score Score   
General Neuro Cardio Renal Total  
ERT-treated 
1 m Cardiac  7 5 18 15 45 
2 m General  9 4 10 10 33 
3 f General  8 3 7 5 23 
4 f Renal 5 3 5 10 23 
5 m Cardiac  5 4 15 6 30 
6 f General  8 8 8 8 32 
7 f Cardiac  5 5 14 6 30 
8 f Renal   5 5 10 15 35 
9 m General  10 5 10 10 35 
10 m Cardiac  7 5 15 10 37 
11 m General  10 5 6 6 27 
12 m Renal  5 5 10 15 35 
13 f General  10 5 8 7 30 
14 m Cardiac  5 5 15 8 33 
15 m General  10 3 10 10 33 
16 m General  10 5 12 12 39 
17 f General  10 5 15 10 40 
18 m General  10 5 15 15 45 
19 m Cardiac  10 5 20 15 50 
20 f Cardiac  10 5 18 10 43 
21 f Cardiac  8 5 18 10 41 
22 m General  10 10 10 10 40 
23 f Renal 10 5 10 15 40 
24 m General  10 10 10 10 40 
25 m Renal 10 10 10 15 45 
26 f General  10 10 10 10 40 
27 f General  10 10 10 10 40 
28 f General  10 10 10 10 40 
29 f Renal 10 5 10 15 40 
30 f Cardiac  10 5 18 10 43 
31 f Cardiac  10 5 18 10 43 
32 m Renal 10 10 10 15 45 
Untreated  
33 f General  8 3 7 5 23 
34 f Renal 5 3 5 10 23 
35 m Cardiac  5 4 13 6 28 
36 f General  8 8 8 8 32 
37 m Cardiac  5 5 14 6 30 
38 f Renal 5 5 10 10 30 
39 m General  10 5 10 10 35 
40 m Cardiac  7 5 12 10 35 
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To identify putative miRNA biomarkers in FD patients we will implement a 
screening strategy composed of two successive steps.  
In the first step we will perform a small RNA-Seq profiling of plasma following 
the previously described protocol in a small subset (n=5) of patients with 
advanced stage FD. 
The second step will consist in the validation of a sub-set of miRNAs identified 
both from the analysis of patients and of the FD mouse in the whole cohort of 
FD patients (n=40, see above) using Quantitative (q) Reverse Transcriptase 
(RT-) PCR (qRT-PCR) miRNA profiling.  
 
Materials and methods 
A FD knockout mouse model was purchased form Jackson laboratories and is 
available in our laboratory. FD knockout mouse model was generated by 
introducing a 1 kb deletion into the GLA gene, spanning part of exon III and 
intron III. The mouse model completely lacks alpha-Gal A and shows the 
pathologic features of FD, with accumulation of substrates in the kidneys, liver, 
and in cultured fibroblasts. Ultrastructural analysis reveals concentric lamellar 
inclusions in kidneys. The FD mouse model has been purchased from 
Jackson Labs and is already available in our laboratory. 
 
A total of 40 patients followed at the Department of Public Health, Section of 
Nephrology, Federico II University, Naples, Italy are already available for our 
study.  
The approval of the local Ethical Committee will be obtained before enrollment 
of patients, according to standard local procedures. Patients will sign an 
informed consent to allow the use of samples for research purposes. 
Plasma will be obtained according to standard procedures during periodic 
follow-up admissions to the Hospital. Five ml of peripheral blood will be 
collected in EDTA and immediately processed, or stored at -800C.  
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Total RNA extraction preserving miRNA fraction, Small RNA-seq analysis in 
tissues, Small RNA-seq analysis in plasma and Bioinformatic Analysis were 
done as indicated previously (materials and methods of chapter 1).  
 
Conclusive remarks 
FD is one of the most common LSD. Also for this disease we have explored 
the potential of miRNAs as new tool for understanding of the diseases 
pathophysiology and as new potential biomarkers to follow disease diagnosis, 
progression and follow up of patients. 
The NGS-based approach showed differentially expressed miRNAs in heart 
and kidney from the FD mouse. NGS screenings at additional time points, 
particularly in more advanced stages of disease,are in progress to better 
characterize the evolution of miRNA abnormalities in FD. As for PD, this 
analysis might result in the identification of circulating DE-miRNAs with 
statistical significance and in the identification of additional tissue-specific DE-
miRNAs in target organs of the disease. To identify putative miRNA 
biomarkers in FD then we will implement our screening strategy on patients. 
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Chapter 3 
Understanding the mechanisms underlying the 
pathophysiology of Pompe disease: inflammation and effect 
of glucocorticoids. 
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Introduction 
Inflammation and muscle in PD 
Some observations suggest that inflammation may play an important role in 
the pathophysiology of LSDs in general, including PD. Inflammation has been 
recently described in some LSDs, such as Multiple Sulfatase Deficiency or 
Niemann-Pick disease type C1 [Einat et al, 2010]. Nothing is known about the 
possible role of inflammation in PD muscle.  
Strenuous muscle exertion or injuries typically initiate a rapid and sequential 
invasion of muscle by inflammatory cell populations that can persist for days 
to weeks, while muscle repair, regeneration, and growth occur. This 
relationship between inflammation and muscle repair or regeneration has 
suggested that they may be mechanistically related and provides the basis for 
the idea that muscle inflammation after injury is a functionally beneficial 
response. However, experimental observations have only recently begun to 
test that hypothesis and to distinguish between features of muscle 
inflammation that promote injury and those that promote growth or repair 
[James et al, 2005]. 
Macrophages play an essential role in the immune response and normal 
tissue development by producing proinflammatory mediators and by 
phagocytic clearance of pathogens and apoptotic cells [Lombardo et al, 2007; 
Bosca et al, 2005]. It has been described that macrophages could undergo 
different activation processes depending on the stimuli received.   
- The classic activation, which can be induced by in vitro culture of 
macrophages with IFN-g and LPS (inducing TNF-a production), is 
associated with high microbicidal activity, proinflammatory cytokine, 
and reactive oxygen species production and cellular immunity;  
- the innate activation, which is mediated in culture by ligation of 
receptors, such as TLRs, is associated with microbicidal activity and 
proinflammatory cytokine production;  
- the alternative activation, which can be mimicked in vitro after culture 
with IL-4, IL-13, glucocorticoids, immune complexes, or IL-10, is 
associated with tissue repair, tumor progression, and humoral immunity 
[Gordon et al, 2005; Mantovani et al, 2005]. 
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Pathways involved in the activation of inflammation  
There are several pathways which may have an important (albeit poorly 
known) role in inflammation and muscle damage in PD.  
Nuclear Factor Kappa B (NF-kB) is a major trascription factor espressed in 
wide variety of cells and modulating the cellular immune, inflammatory and 
proliferative responses [Karin, 1999]. 
Recently, the role of NF-kB in the skeletal muscle wasting process is gaining 
increasing attention, mainly because NF-kB is activated in response to 
several inflammatory molecules that cause muscle loss [Messina et al, 2011; 
Messina et al, 2006]. 
The inhibition of NF-kB activity by GCs is relevant for their anti-inflammatory 
action [Ana et al, 2007]. Moreover an involvement of NF-kB in myogenesis 
has been suggested because its activity was shown to be required by human 
and rat myoblasts to fuse into myotubes and to express muscle-specific 
proteins, such as myosin heavy chain and claveolin3 [Kaliman et al, 1999]. It 
has also been demonstrated that systemic administration of the NF-kB 
inhibitor curcumin stimutales muscle regeneration after traumatic injury, 
suggesting that modulation of NF-kB activity within muscle tissue could be 
beneficial for muscle repair [Thaloor et al, 1999]. 
The study of this pathway in PD skeletal muscle and heart could help in 
understanding of PD physiopathology and colud provide new therapeutic 
targets. 
 
Effects of glucocorticoids 
Pompe patients are caracterized by increased levels of muscular isoform of 
creatin-kinase (CK), as marker of muscular damage. Our unpublished 
experience suggests that when PD patients, occasionally and for intercurrent 
illnesses, are treated by steroid therapy, show a substantial reduction of CK 
levels. This reduction is temporary and ends when steroid therapy is 
discontinued.  
Glucocorticoids (GCs), have a key role in maintaining muscle integrity. Many 
stress conditions are accompanied by skeletal muscle dysfunction and 
regeneration, which is essentially a recapitulation of the embryonic 
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development. However, regeneration usually occurs under conditions of 
hypothalamus-pituitary-adrenal gland axis activation and therefore increased 
GCs levels. Skeletal muscle is a prominent target for GCs in healt and 
disease [Schweicker et al, 2007; Menconi et al, 2007; Glass et al, 2010]. 
GCs are currently the only effective pharmacological treatment for Duchenne 
muscular dystrophy, where degeneration-regeneration cycle is a prominent 
feature, and they were even reported to enhance differentiation in skeletal 
muscle precursors from mdx mice [Passaquin et al 1993; Bach et al, 2010; 
Matthews et al, 2010; Ciciliot et al, 2010]. The benefical effect of steroid 
therapy in slowing the progression of DMD has been widely demonstrated in 
the literature [Mendell et al, 1989; Biggar et al, 2006]. A recent paper reports 
the ultrastructural changes following steroid therapy in dystrophic muscles. 
The presence of morphological changes following steroid therapy supports 
the beneficial therapeutic effects of steroids in muscle dystrophy. In this 
regard, further investigations are required to determine if these steroid-
associated ultrastructural changes reflect underlying molecular changes. In 
particular steroid therapy in dystrophic muscle is associated with reduced 
numbers of dendritic cells and fibroblasts and increased numbers of satellite 
cells [Mahmoud et al, 2010]. Moreover the anti-infiammatory action of GCs 
result also from the inhibition of the activity of trascription factors as NF-kB by 
different mechanisms. 
Based on these premises it would be interesting to investigate a possible role 
of GCs effect on muscular damage in PD.  
Data on GCs signaling during human skeletal muscle regeneration, which is 
characterized by satellite cell activation, myoblast proliferation, fusion into 
myotubes and later by (re)innervation and maturation into fully developed 
muscle fibers [Chargè et al, 2004; Ciciliot et al, 2010], remain still incomplete. 
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Objectives 
Other aim of the project is to investigate the presence and the role of 
inflammation in muscles of PD mice and patients and to identify possible 
target of innovative therapeutic strategy for PD. It would also be interesting to 
investigate a possible role of GCs effect on muscular damage in PD. Data on 
GCs signaling during human skeletal muscle regeneration remain still 
incomplete and the benefical effect of steroid therapy on muscle is a 
controversial topic.  
 
Preliminary results 
Our preliminary experiment to understand whether inflammation is present or 
not in PD muscles showed infiltrating macrophages among muscle fibers of 
PD mice.  
The experiment was performed in muscle from PD mice at different ages (3 
months and 9 months), that represented different stages of the disease 
progression. The presence of infiltrating macrophages was already detectable 
at 3 months, but was more appreciable at 9 months compared to control 
healty mouse muscle (as shown in FIGURE 10). 
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FIGURE 10 
 
Muscle  tissue (quadriceps) was stained with a macrophages specific marker (cd68) in red 
and with a basal lamina specific marker (laminin) in green. 
 
Ongoing objective 
Objective 1: To study the expression of different cytokines and 
additional markers of inflammation at different and more advantaged 
time points. This  study in necessary to better characterize inflammation in 
PD, that is a field little knonw in this disease. 
 
Objective 2: To study the effect of GC in-vivo. At this aim PD mice at 
different ages will be injected with selected GCs and then will be evaluate 
their effect at different time post injection.  
Objective 3: correlation  
 
 
Conclusive remarks 
This part of the project is in a very preliminary phase. We have shown the 
presence of inflammation in PD mouse model muscle, a pathologic finding 
that has never been reported in earlier studies. This finding may be potentially 
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relevant for the identification of additional targets of therapy in PD and the 
development of multidisciplinary therapeutic strategies.     
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Chapter 4 
Lysosomal enzymes assays in study of Wilson disease 
(collaboration) 
 
“Wilson Disease Protein ATP7B Utilizes Lysosomal 
Exocytosis to Maintain Copper Homeostasis” 
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Introduction 
 
Copper is an essential yet toxic metal and its overload causes Wilson 
disease, a disorder due to mutations in copper transporter ATP7B. To remove 
excess copper into the bile, ATP7B traffics toward canalicular area of 
hepatocytes. However, the trafficking 
mechanisms of ATP7B remain elusive. Here, we show that, in response to 
elevated copper, ATP7B moves from the Golgi to lysosomes and imports 
metal into their lumen. ATP7B enables lysosomes to undergo exocytosis 
through the interaction with p62 subunit of dynactin that allows lysosome 
translocation toward the canalicular pole of hepatocytes. 
Activation of lysosomal exocytosis stimulates copper clearance from the 
hepatocytes and rescues the most frequent Wilson-disease-causing ATP7B 
mutant to the appropriate functional site.  
 
I have collaborated at this project since I have experience in the field of 
lysosomal enzymatic assays. Determination of b-Galattosidase and b-
Hexosaminidase activities have been useful to understand the final findings of 
this study: they indicated that lysosomes serve as an important intermediate 
in ATP7B trafficking, whereas lysosomal exocytosis operates as an integral 
process in copper excretion and hence can be targeted for therapeutic 
approaches to combat Wilson disease. 
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Copper is an essential yet toxic metal and its over-
load causes Wilson disease, a disorder due to
mutations in copper transporter ATP7B. To remove
excess copper into the bile, ATP7B traffics toward
canalicular area of hepatocytes. However, the traf-
ficking mechanisms of ATP7B remain elusive. Here,
we show that, in response to elevated copper,
ATP7B moves from the Golgi to lysosomes and im-
ports metal into their lumen. ATP7B enables lyso-
somes to undergo exocytosis through the interaction
with p62 subunit of dynactin that allows lysosome
translocation toward the canalicular pole of hepato-
cytes. Activation of lysosomal exocytosis stimulates
copper clearance from the hepatocytes and rescues
the most frequent Wilson-disease-causing ATP7B
mutant to the appropriate functional site. Our find-
ings indicate that lysosomes serve as an important
intermediate in ATP7B trafficking, whereas lyso-
somal exocytosis operates as an integral process in
copper excretion and hence can be targeted for ther-
apeutic approaches to combat Wilson disease.
INTRODUCTION
Copper is an indispensable micronutrient because a number of
enzymes require it as a cofactor for fundamental metabolic pro-
cesses such as respiration; free radical scavenging; pigmenta-
tion; and synthesis of collagen, elastin, and neurotransmitters
(Lutsenko, 2010; Nevitt et al., 2012). However, due to its redox
potential, copper can induce cellular toxicity. To avoid toxic
accumulation of Cu, vertebrates developed a fine-tuned mecha-686 Developmental Cell 29, 686–700, June 23, 2014 ª2014 The Authnism that allows excess Cu to be removed from the organism
through the Cu-transporting ATPase ATP7B. ATP7B is a large
multidomain protein with eight transmembrane helices, which
form a channel that pumps Cu from the cytosol at the expense
of ATP hydrolysis (Figure 1A). ATP7B is highly expressed in liver,
where it normally resides in the trans-Golgi network (TGN) of
hepatocytes and loads Cu on newly synthetized ceruloplasmin,
the major Cu-carrying protein in the blood (Lutsenko, 2010).
When intracellular Cu levels increase, ATP7B is thought to traffic
toward the biliary surface of hepatocytes and associated ‘‘vesi-
cles’’ involved in the excretion of Cu into bile. Mutations in the
ATP7B gene frequently result in the failure of its protein product
to traffic to the sites of Cu excretion. This defect causes toxic
accumulation of Cu in the liver and, as a consequence, develop-
ment of Wilson disease that is fatal if not treated in time (Gupta
and Lutsenko, 2009).
Despite the fundamental role of ATP7B trafficking in Cu
homeostasis, the intracellular itinerary of ATP7B transport re-
mains poorly understood and controversial (La Fontaine and
Mercer, 2007; Polishchuk and Lutsenko, 2013). First, in contrast
to common view, several studies conducted in hepatic cells indi-
cate that Cu does not alter the intracellular distribution of ATP7B
(Harada et al., 2000, 2005). Second, the uncertainty in ATP7B
trafficking concerns the identity of the peripheral vesicular struc-
tures, whose ability to receive ATP7B upon Cu overload was
associatedwith aCu excretion process (La Fontaine andMercer,
2007; Polishchuk and Lutsenko, 2013). The majority of studies
failed to demonstrate any significant overlap between ATP7B
vesicles and common exo- or endocytic markers (Guo et al.,
2005; La Fontaine et al., 2001), whereas few publications re-
ported a fluorescent ATP7B fusion protein within the late endo-
some compartment (Harada et al., 2000, 2005). Therefore, the
simple term ‘‘vesicles’’ is often applied to ATP7B-positive struc-
tures because lack of coherent data identifying their molecular
composition and ultrastructure makes it problematic to classify
them as specific exo- or endocytic organelles. Finally, theors
Figure 1. Increasing Cu Concentration Triggers ATP7B Trafficking from the TGN to LE/Lysosome Compartments
(A) Schematic structure of ATP7B. Black balls show N-terminal metal-binding domains. Numbers indicate transmembrane helices. The domains, which regulate
ATPase activity, are indicated in italic with D residue for catalytic phosphorylation and with most frequent WD-causing mutation, H1069Q (yellow star).
(B) HepG2 cells were fixed after overnight exposure to 200 mM BCS and stained for endogenous ATP7B and golgin 97.
(C) BCS-treated cells were washed and incubated with 200 mMCuSO4 for 2 hr. Confocal microscopy reveals endogenous ATP7B in vacuolar structures (arrows),
which did not contain Golgin 97 or EEA1 but were decorated by LAMP1.
(D) Quantification shows ATP7B colocalization (mean ± SD; n = 50 cells) with lysosomal markers.
(E) Percentage (mean ± SD; n = 20 fields) of the cells with ATP7B in the TGN or in the lysosomes was calculated for treatments with BCS or with different
concentration of CuSO4 (as indicated along x axis).
(F and G) HepG2 cells were infected with adenovirus carrying ATP7B-GFP (adeno-ATP7B-GFP) and incubated with BCS. Then, the cells were fixed either directly
(F) or after 2 hr incubation with CuSO4 (G) and immunogold labeled to reveal ATP7B-GFP. Arrows indicate ATP7B signal over the TGNmembranes in low Cu (F) or
over the MVB/lysosome-like structures (G) in elevated Cu. Arrowheads show ATP7B at the cell surface in cells exposed to CuSO4 (G).
(H) Pie plots exhibit percentage of ATP7B-associated gold particles in different compartments in cells treated with BCS or CuSO4. EE, early endosome.
The scale bars represent 5 mm (B and C) or 250 nm (F and G).
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ATP7B-Driven Lysosome Exocytosis in Cu Homeostasisquestion on whether or not ATP7B really reaches the canalicular
surface of hepatocytes became the issue of ongoing debate
(Hubbard and Braiterman, 2008).
As a consequence of above gaps in understanding of ATP7B
trafficking, it is yet to be determined (1) which transport route
is employed by ATP7B to reach ‘‘vesicles’’ and from where it
emerges, (2) whether and how ATP7B gets delivered from ‘‘ves-
icles’’ to the canalicular surface of hepatocytes, and (3) how
ATP7B trafficking is coordinated with Cu excretion from the cell.
Here, we show that an increase in Cu concentration induces
direct ATP7B trafficking from the TGN to a subset of lysosomes,
where ATP7B imports Cu for storage in the lysosome lumen and
through the interaction with p62 subunit of dynactin complex
enables lysosomes for polarized exocytosis at the canalicular
surface of hepatocytes. Activation of lysosomal exocytosis
stimulates both the delivery of ATP7B and its Wilson-disease-
causing mutant to the canalicular membrane domains of hepa-
tocytes and the release of excess Cu into the bile. Thus, our
findings indicate ATP7B-containing lysosomes and lysosomal
exocytosis as key components of Cu homeostasis.
RESULTS
Cu Induces ATP7B Redistribution from the TGN to Late-
Endosome/Lysosome Compartments
We first investigated trafficking and localization of ATP7B in hep-
atoma HepG2 cells under different conditions varying in Cu
levels. HepG2 cells express endogenous ATP7B and maintain
key properties of normal hepatocytes, representing a reliable
system to investigate trafficking of human ATP7B (Cater et al.,
2006; Roelofsen et al., 2000). Figure 1B shows that Cu chelation
with bathocuproine disulphonate (BCS) resulted in ATP7B accu-
mulation in the Golgi region, where ATP7B colocalized with the
TGN marker golgin-97. To stimulate ATP7B trafficking from the
TGN, BCS-treated cells were washed and exposed to 200 mM
CuSO4 for 2 hr. This resulted in complete loss of the ATP7B
from the TGN and its relocation to peripheral vesicular structures
(Figure 1C, arrows). To determine whether these structures
belong to an annotated exo- or endocytic compartment, we
tested a battery of markers for overlap with the endogenous
ATP7B. Confocal microscopy revealed significant colocalization
between ATP7B and the late-endosome (LE)/lysosome markers
LAMP1, CD63, and LBPA in the vesicular structures (Figures 1C
and 1D and Figure S1A available online). In addition, we analyzed
the distribution of the S340A mutant of ATP7B, which constantly
resides in ‘‘vesicular’’ compartments (Hasan et al., 2012), and
found its robust overlap with LAMP1 (Figure S1B). These obser-
vations suggest that ATP7B traffics from the TGN to the LE/lyso-
some compartment in response to elevated Cu. This process
was extremely sensitive to Cu. Even relatively low (5–20 mM)
Cu concentration induced ATP7B trafficking to LE/lysosomes
(Figure 1E). Importantly, we also found LAMP1-, CD63-, and
LBPA-positive organelles without ATP7B signal, indicating that
only a subset (about 40%) of the LE/lysosomes received
ATP7B from the TGN (Figure S1C).
To further verify LE/lysosomal targeting of ATP7B, we em-
ployed immuno-electron microscopy (EM) analysis of ATP7B-
GFP that exhibited trafficking and localization similar to the
endogenous ATP7B (Figure S1D). In response to Cu, ATP7B-688 Developmental Cell 29, 686–700, June 23, 2014 ª2014 The AuthGFP moved from the tubular-vesicular TGN membranes (Fig-
ure 1F, arrows) to large multivesicular body (MVB)-like structures
(Figure 1G, arrows; see also morphometry in Figure 1H), which
contained numerous intraluminal vesicles (ILVs) and/or hetero-
geneous electron dense material (Figures 2A and 2B). These
ultrastructural features allowed us to assign ATP7B-containing
organelles to the LE/lysosome compartment (Saftig and Klum-
perman, 2009). Indeed, a double immunogold labeling revealed
ATP7B-positive MVBs to contain LAMP1 (Figure 2B). Finally,
we verified whether ATP7B is also transported to LE/lysosomal
structures in vivo. Thin sections of mice liver revealed ATP7B-
GFP (expressed via adenoviral vector) in MVB-like structures
decorated by LAMP1 (Figure 2C) and similar to those observed
in HepG2 cells. Therefore, ATP7B ‘‘vesicles’’ in the HepG2 line
and in mouse hepatocytes can be defined as LE/lysosomes
from both molecular and ultrastructural standpoints (for con-
venience, we will call them ‘‘lysosomes’’ through the rest of the
manuscript).
Lysosomal localization of ATP7B prompted us to investigate
whether the protein is directed to lysosomes for degradation
that requires sorting into ILVs located in the lumen of lysosomes
(Saftig and Klumperman, 2009). We found that only a small frac-
tion of ATP7B was associated with ILVs and lysosome lumen
(Figures 2A–2E), even when compared to LAMP1 (Figures 2A
and 2E). Correspondingly, ATP7B levels remained unaffected
when lysosome degradation was inhibited with bafilomycin A
(Figure S2), indicating that ATP7B is targeted to lysosomes to
perform a specific function at their limiting membranes, but not
to be degraded.
ATP7B Is Transported to the Lysosomal Compartment
through a Direct Route that Emerges from the TGN
In response to Cu, ATP7B may travel via two possible routes: (1)
it may first be delivered from the TGN to the cell surface and then
be endocytosed to the lysosomes (indirect pathway) or (2)
ATP7B might be conveyed from the TGN directly to the lyso-
somal compartments (direct pathway). To distinguish between
these two possibilities, we treated HepG2 cells with tannic acid
(TA), which blocks both the exo- and endocytic events at the
level of the plasma membrane (Polishchuk et al., 2004). This
treatment would prevent ATP7B trafficking to the lysosomes
through the indirect pathway but would not impact the direct
route. As a control, HepG2 cells were infected with the vesicular
stomatitis virus (VSV) to express a thermosensitive t-45Os
version of VSV glycoprotein (VSVG), a bona fide exocytic marker
(Polishchuk et al., 2003). The cells were incubated at 20C with
BCS to accumulate both VSVG and ATP7B within the Golgi (Fig-
ure 2F). Cells were then shifted to 32C in the presence of CuSO4
to activate both VSVG and ATP7B export from the TGN. In the
absence of TA, VSVG was delivered from the TGN to the cell
surface, whereas TA treatment caused VSVG arrest within
TGN-derived transport carriers, which were docked at the
plasma membrane (PM) but unable to fuse with acceptor mem-
brane (Figure 2F). In contrast, accumulation of ATP7B within
such post-Golgi VSVG-positive carries did not occur. Instead,
most of ATP7B appeared within larger lysosome-like structures
both in control and TA-treated cells (Figure 2F), indicating that
ATP7B traffics directly from the TGN to lysosomes in response
to an increase in Cu concentration.ors
Figure 2. Lysosomes Retain ATP7B at Their
Limiting Membranes and Receive ATP7B
from the TGN through a Direct Route
(A) CuSO4-treated HepG2 cells were immunogold
labeled to reveal either ATP7B-GFP or LAMP1.
Arrows in top panel indicate ATP7B distribution
along limiting membrane of the MVBs, whereas
some LAMP1 labeling can be seen at the internal
membranes of lysosomes (arrow in bottom panel).
(B) CuSO4-treated HepG2 cells were processed
for cryo-immuno-EM. Arrows and arrowheads
indicate ATP7B-GFP and LAMP1, respectively,
within the same lysosome-like structures.
(C) Liver tissue from mice, which was injected with
adeno-ATP7B-GFP and treated with CuSO4, was
labeled for ATP7B-GFP and LAMP1. ATP7B-GFP
(arrows) and LAMP1 (arrowheads) were detected
together within lysosome-like structures.
(D) Quantification of the percentage of gold parti-
cles in lysosomes (mean ± SD; n = 100 structures)
shows most of ATP7B to reside at the external
membrane.
(E) CuSO4-treated HepG2 cells exhibit endoge-
nous ATP7B as circles (arrows) at the surface of
LAMP1-positive structures.
(F) HepG2 cells were infected with VSV (see
Experimental Procedures) and fixed directly after
20C block (left panel) or incubated at 32C with
CuSO4 for 60 min with (right panel) or without
(midpanel) tannic acid (TA). Empty arrows indicate
VSVG at the cell surface (midpanel) and post-Golgi
carriers (right panel), whereas filled arrows indicate
lysosome-like ATP7B structures.
(G) HepG2 cells were fixed directly after incubation
with BCS or exposed to CuSO4 for either 15 min or
60 min and stained for endogenous ATP7B and
LAMP1. Arrows indicate ATP7B/LAMP1-positive
structures.
(H and I) HepG2 cells expressing ATP7B-GFP
were incubated with BCS and fixed directly (H) or
15 min after incubation with CuSO4 (I) and labeled
for ATP7B-GFP and LAMP1. ATP7B and LAMP1
were detected in some TGN domains (H, arrows) of
the Golgi stack (H, asterisk). Arrow in (I) indicates
ATP7B/LAMP1 post-Golgi carrier near the ATP7B/
LAMP1-positive MVBs (arrowheads).
The scale bars represent 250 nm (A), 150 nm (B, C,
H, and I), 3.5 mm (E and F), and 7 mm (G).
Developmental Cell
ATP7B-Driven Lysosome Exocytosis in Cu HomeostasisTo further verify this conclusion, we performed a time course
analysis of ATP7B release from the TGN. As soon as 15 min after
Cu addition, the ATP7B signal was detected in LAMP1-positiveDevelopmental Cell 29, 686–7structures (Figure 2G, arrows). Such a
fast rate of ATP7B trafficking argues
against the indirect pathway because
the uptake from the PM to lysosomes
alone usually takes at least 30 min (Saftig
and Klumperman, 2009). In addition, no
ATP7B was observed at the surface of
hepatocytes at that time point. Later (30
and 60 min after CuSO4 addition), the
number of ATP7B-containing lysosomes
progressively increased, whereas theGolgi area gradually lost the ATP7B signal (Figure 2G), support-
ing the direct transfer of ATP7B from the TGN to the lysosomal
compartments.00, June 23, 2014 ª2014 The Authors 689
Figure 3. ATP7B Delivery to the Canalicular
Domain of Polarized HepG2 Cells Requires
a Lysosome Intermediate
(A) Polarized HepG2-MDR1 cells were fixed directly
after incubation with BCS or after additional treat-
ment with CuSO4 for either 2 hr or 8 hr. After incu-
bation with BCS, ATP7B was detected mainly
within Golgi membranes (red arrows) but neither in
CD63-positive lysosomes (blue arrows) nor in
canalicular vacuoles (green arrows). Exposure to
CuSO4 (2 hr) triggered ATP7B relocation to CD63-
positive structures (pink arrows), which were
frequently clustered around apical cysts (green
arrows). White arrows in the lower row show
canalicular vacuole, which received both ATP7B
and CD63 after 8 hr incubation with CuSO4.
(B) The percentage (mean ± SD; n = 20 fields) of
ATP7B-positive or CD63-positive canalicular vac-
uoles increased in HepG2 cells over the time of
incubation with CuSO4.
(C) The cells were treated like in (A) with the
exception that different CuSO4 concentrations
were utilized. The percentage (mean ± SD; n = 20
fields) of ATP7B-positive canalicular vacuoles was
calculated and plotted as a function of time.
(D) Polarized HepG2-MDR1 cells were with BCS
overnight or with CuSO4 for only 8 hr. The activity of
b-Gal (mean ± SD; n = 3 experiments) in the
canalicular cysts exhibits increase upon Cu stimu-
lation.
The scale bar represents 6.5 mm (A).
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ATP7B-Driven Lysosome Exocytosis in Cu HomeostasisWe next investigated which Golgi-to-lysosome pathway is
utilized by ATP7B. A large cohort of lysosomal proteins is carried
from the TGN to endolysosomal compartments through trans-
port events driven by clathrin and its adaptors, AP-1 and GGA
(Saftig and Klumperman, 2009), whereas other lysosome resi-
dents (such as LAMP1 and MHC-II) take a clathrin-independent
TGN-to-lysosome route (Pols et al., 2013; Saftig and Klumper-
man, 2009). We found that ATP7B did not associate with cla-
thrin-coated profiles (Figure 1F, arrowheads) in the TGN area
under neither low nor high Cu conditions. This is consistent
with recent observations that neither AP-1 nor GGA suppression
affects ATP7B export from the Golgi (Hirst et al., 2012). Further
examination revealed ATP7B enrichment over the smooth TGN
membrane domains (arrows in Figures 1F and 2H), which often
contained LAMP1 (Figure 2H, arrows). Shortly after Cu stimula-
tion, ATP7B was detected within 70–200 nm round or elongated
membrane carriers, which occasionally exhibited internal mem-
branes (Figure 2I, arrow) and therefore were similar to structures
operating in direct Golgi-to-lysosome transport of LAMP1 (Pols
et al., 2013). Indeed, these ATP7B carriers also frequently con-
tained LAMP1 and were docked to the MVB-like structures (Fig-
ure 2I), indicating that ATP7B and LAMP1 may use the same
pathway to travel from the TGN to lysosomal compartments.
ATP7B Is Delivered from Lysosomes to Canalicular PM
in Polarized Hepatocytes
ATP7B trafficking to lysosomes in response to Cu was unex-
pected and raised a question about the mechanism through
which the lysosomes mediate Cu excretion from hepatocytes.690 Developmental Cell 29, 686–700, June 23, 2014 ª2014 The AuthOne possibility would be that Cu efflux occurs through lysosomal
exocytosis, a mechanism by which lysosomes fuse with the PM
and secrete their content to the outside the cell (Andrews, 2000).
To examine whether ATP7B-containing lysosomes undergo
apical exocytosis, we grew HepG2 cells under conditions that
allowed for their polarization (Slimane et al., 2003). Upon polari-
zation, neighboring hepatocytes form an apical (or biliary) cyst
(vacuole) enriched in specific apical markers such as biliary
salt transporters MDR1, MRP2, etc. (Slimane et al., 2003). Polar-
ized HepG2 cells stably expressing canalicular marker MDR1-
GFP (Slimane et al., 2003) were incubated with BCS to trap
ATP7B within the Golgi and then exposed to 200 mM CuSO4 to
follow the fate of ATP7B. In low Cu, ATP7B was mostly detected
in the Golgi area (Figure 3A). Two hours after Cu stimulation,
ATP7B exhibited a significant overlap with CD63 in lysosomes,
which were frequently clustered around the biliary surface of
the cells (Figure 3A). Notably, over 40% of apical cysts already
exhibited ATP7B signal at this time point (Figure 3B). When
incubation with CuSO4 was extended to 8 hr, the ATP7B labeling
became more evident in canalicular cysts with 60% of them
being ATP7B positive (Figures 3A and 3B). We also found that
the redistribution of ATP7B to the canalicular domain of the
cells occurred even upon moderate Cu increase (20–40 mM)
and correlated with concentration of Cu and the duration
of CuSO4 treatment (Figure 3C). A lower concentration of
Cu (10 mM) was unable to induce ATP7B delivery to the canalic-
ular membrane of HepG2 cells, although it still allowed for effi-
cient ATP7B redistribution from the TGN to lysosomes (see
Figure 1E).ors
Figure 4. Activation of Lysosomal Exocy-
tosis Stimulates Delivery of ATP7B to the
Plasma Membrane
(A) HeLa or CF7 cells were infected with adeno-
ATP7B-GFP, incubated with CuSO4 for 2 hr, fixed,
and stained for LAMP1. Arrows indicate ATP7B in
lysosomes.
(B and C) HeLa (B) or CF7 cells (C) were treated as
in (A) and processed for immunogold EM to reveal
ATP7B-GFP distribution. In both cell types,
elevated Cu triggered ATP7B delivery to the
lysosome-like structures (B and C, arrows) and
plasma membrane (B and C, arrowhead).
(D) Morphometry revealed reduction of the dis-
tance (mean ± SD; n = 100 lysosomes) between
lysosomes and PM in CF7 cells.
(E) Arrowhead indicates the site of fusion between
ATP7B-positive lysosome (arrows) and PM in CF7
cell.
(F) Pie plots exhibit percentage of ATP7B-associ-
ated gold particles in different compartments of
HeLa and CF7 cells.
(G) HeLa and CF7 cells were infected with adeno-
ATP7B-GFP and then prepared for surface bio-
tinylation directly or 2 hr after stimulation with
200 mM CuSO4. Western blot revealed higher
amount of ATP7B at the surface of CF7 cells upon
Cu increase.
The scale bars represent 3.8 mm (A), 280 nm (B),
240 nm (C), and 220 nm (E).
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ATP7B-Driven Lysosome Exocytosis in Cu HomeostasisInterestingly, we also detected CD63 together with ATP7B in
the apical vacuoles upon Cu stimulation (Figures 3A and 3B).
This suggests that ATP7B and CD63 were delivered together
to the apical cysts of hepatocytes, likely through the induction
of lysosomal exocytosis in response to Cu stimulation. Indeed,
ATP7B delivery to the canalicular area of hepatocytes coincided
with an increase in activity of lysosomal enzyme b-galactosidase
(b-Gal) in biliary cysts upon Cu stimulation (Figure 3D).
Thus, apical lysosomal exocytosis may serve as a main route
for Cu excretion in hepatocytes because it allows for (1) release
of Cu from the ATP7B-positive lysosomal stores and (2) delivery
of ATP7B to the canalicular domain.
Modulation of Lysosomal Exocytosis Affects ATP7B
Delivery to the PM
Given that lysosomal exocytosis seems to be involved in the de-
livery of ATP7B to the cell surface, we decided to verify whether
modulation of this process impacts ATP7B trafficking to the PM.
To this end, we first used the CF7 HeLa cells that stably overex-Developmental Cell 29, 686–7press transcription factor EB (TFEB), a
potent activator of lysosomal exocytosis
(Medina et al., 2011). Stimulation with
CuSO4 induced ATP7B redistribution
from the Golgi to lysosomes and PM in
both CF7 and parental HeLa cells (Fig-
ure 4A). CF7 cells exhibited ATP7B in
numerous LAMP1-positive lysosomes
positioned close to the peripheral regions
of the cell membrane (Figure 4A). Such
LAMP1-positive structures constitute apool of peripheral lysosomes that actively undergo exocytosis
(Medina et al., 2011). Indeed, EM revealed ATP7B in lysosome-
like structures that were located significantly closer to the PM
in CF7 cells than in control HeLa cells (Figures 4B and 4C,
arrows, and 4D). Importantly, ATP7B-positive lysosomes were
frequently seen to fuse directly with the PM in CF7 cells (Fig-
ure 4E), resulting in increase in the amount of ATP7B compared
to the parental HeLa line (Figure 4F), as also confirmed by sur-
face biotinylation (Figure 4G). Taken together, these observa-
tions suggest that TFEB-mediated activation of lysosomal
exocytosis stimulates ATP7B delivery to the cell surface under
high Cu conditions.
To test whether this is also the case in a liver-relevant cell
system, polarized MDR1-GFP HepG2 cells were infected with
a helper-dependent adenovirus carrying TFEB DNA (HDAd-
TFEB) (Figures 5A–5D), which resulted in an increase in TFEB
expression (Figure 5C). TFEB- and mock-infected cells
were then exposed to CuSO4, and the ATP7B signal in MDR1-
GFP-positive biliary cysts was analyzed. We found that00, June 23, 2014 ª2014 The Authors 691
Figure 5. Modulation of Lysosomal Exocy-
tosis Impacts ATP7B Delivery to the Cana-
licular Domains of Hepatic Cells In Vitro
and In Vivo
(A) Polarized HepG2-MDR1 cells were infected
with HDAd-TFEB (middle column) or incubated
with MCOLN1-specific small interfering RNAs
(siRNAs) (right column) and exposed to 200 mM
CuSO4 for 8 hr. Immunofluorescent labeling
of endogenous ATP7B revealed increase in its
amount in the area of canalicular vacuoles (arrows
in the midcolumn) in the cells infected with HDAd-
TFEB and decrease in the canalicular area (arrows
in the right column) of MCOLN1-silenced cells.
(B) Quantification shows ATP7B-associated fluo-
rescence in the MDR1-positive canalicular vacu-
oles (mean ± SD; n = 50 canalicular vacuoles).
(C) qRT-PCR indicated increase in TFEB mRNA
levels in the cells infected with virus containing
TFEB DNA.
(D) Western blot revealed that total amounts of
endogenous ATP7B remained similar in control
and TFEB-overexpressing cells.
(E) qRT-PCR shows decrease in MCOLN1 mRNA
levels in MCOLN1-silenced cells.
(F and G) Liver tissue from the control and Tcfeb-
LiKO mice injected with adeno-ATP7B-GFP were
prepared for cryo-immuno-EM, which revealed
ATP7B (F, arrows) and LAMP1 (F, arrowheads) in
the canalicular region (F, asterisk) in control mice.
LAMP1 (G, arrowheads) and ATP7B (G, arrows)
exhibited poor signal at the canalicular membrane
(G, asterisk) in Tcfeb-LiKOmice but were detected
in neighbor lysosome (G, open arrow).
(H) ATP7B and LAMP1 labeling densities were
calculated in canalicular domains (mean ± SD; n =
50 canalicular areas) and in lysosomes (mean ±
SD; n = 50 lysosomes).
The scale bars represent 3.5 mm (A), 240 nm (F),
and 270 nm (G).
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ATP7B-Driven Lysosome Exocytosis in Cu Homeostasisoverexpression of TFEB resulted in a higher amount of ATP7B
delivered to the apical domain of HepG2 cells (Figures 5A and
5B), whereas the total quantity of ATP7B remained the same
(Figure 5D).
In a parallel series of experiments, we inhibited lysosomal
exocytosis by suppressing mucolipin-1 (MCOLN1) using RNAi.
MCOLN1 is a Ca2+ channel, which promotes lysosome fusion
with PM (Medina et al., 2011). Reduction of MCOLN1 expression
in HepG2 cells (Figure 5E) resulted in a significant decrease in
ATP7B delivery to biliary surface (Figures 5A and B). Given that
Ca2+ is required for lysosomal exocytosis (Andrews, 2000), we
used the Ca2+ chelator BAPTA as another tool to inhibit lyso-
somal exocytosis and observed reduction in ATP7B trafficking
to the canalicular domain in BAPTA-treated cells (not shown).
Finally, we employed a mice model with a liver-specific
knockout of TFEB (Tcfeb-LiKO mice) (Settembre et al., 2013)
to evaluate whether inhibition of TFEB-mediated lysosomal
exocytosis affects delivery of ATP7B to the canalicular sites of
hepatocytes in vivo. To this end, control and Tcfeb-LiKO mice
were given Cu in their drinking water as described (Gross
et al., 1989). The mice were sacrificed 4 hr after stimulation
with Cu and their livers processed for analysis. EM revealed spe-
cific ATP7B and LAMP1 signals in canalicular area of hepato-692 Developmental Cell 29, 686–700, June 23, 2014 ª2014 The Authcytes in the liver of control mice (Figure 5F), indicating efficient
delivery of both proteins from the lysosomes upon Cu overload.
The presence of ATP7B and LAMP1 at the canalicular mem-
brane of hepatocytes correlated with increased activity of
b-Gal and b-hexosaminidase (b-Hex) in the bile (Figure S3A).
This suggests that Cu stimulates lysosomal exocytosis at the
biliary surface of hepatocytes and thus facilitates ATP7B delivery
from lysosomal structures to the canalicular membrane.
In contrast, TFEB deletion in the liver of Tcfeb-LiKO mice
resulted in significant reduction of both ATP7B and LAMP1
labeling at the biliary membrane of hepatocytes (Figures 5G
and 5H). We reasoned that the decrease of ATP7B at the
canalicular domains in Tcfeb-LiKO mice liver was due to the
suppression of lysosomal exocytosis. We found that ATP7B/
LAMP1-positive lysosomes can be detected near canaliculi (Fig-
ure 5G) in Tcfeb-LiKO mice and that ATP7B/LAMP1 labeling
densities in such lysosomes were similar to those in control
animals (Figure 5H). However, deletion of Tcfeb did not allow
ATP7B lysosomes to fuse with apical membrane of hepatocytes
and therefore to convey ATP7B to the canalicular surface. This
correlated with a significant reduction of b-Hex and b-Gal acti-
vities in the bile of Tcfeb-LiKO mice despite Cu stimulation
(Figure S3B).ors
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ATP7B-Driven Lysosome Exocytosis in Cu HomeostasisThus, taken together, both in vitro and in vivo observations
support the involvement of lysosomal exocytosis in targeting
ATP7B to the biliary surface domain in hepatic cells.
Activation of Lysosomal Exocytosis Increases Copper
Excretion from the Cells
To further test the impact of lysosomal exocytosis on Cu homeo-
stasis, we investigated whether this process is involved in the
regulation of Cu efflux from liver cells. Coppersensor 3 (CS3)
was employed to analyze intracellular levels of exchangeable
Cu (Dodani et al., 2011). Variations of intracellular Cu levels
observed in the control experiments with CS3 (Figures 6A and
6B) were confirmed by spectroscopy (Figure 6C).
Then, we investigated subcellular distribution of CS3 in cells
expressing ATP7B-GFP. HepG2 cells treated with BCS ex-
hibited low CS3 signal in the cytoplasm, whereas ATP7B-GFP
was mainly detected in the Golgi area (Figure 6D). Shortly
(15 min) after exposing cells to Cu, ATP7B appeared in the
lysosomes where increased CS3 signal was detected (Fig-
ure 6D). Longer incubation with CuSO4 (up to 2 hr) induced a
complete redistribution of ATP7B to the lysosomes (Figure 6D),
where CS3 fluorescence further concentrated, indicating that
ATP7B lysosomes could be used for temporary Cu storage/
sequestration.
Next, we reasoned that activation of lysosomal exocytosis
should allow reduction of intracellular Cu due to release of the
metal from the lysosome into canalicular vacuoles. To test this,
we used polarized HepG2 cells, which were infected with
HDAd-TFEB to activate lysosomal exocytosis, exposed to
CuSO4, and labeled with CS3. Confocal microscopy revealed
the CS3 signal to be higher in biliary cysts of TFEB-overexpress-
ing cells than in those of control cells (Figures 6E–6G). Mean-
while, CS3 fluorescence decreased in the cytoplasm of TFEB-
infected cells (Figure 6E). Elevation of Cu levels in the apical
vacuoles of TFEB-overexpressing HepG2 cells was confirmed
by inductively coupled plasma mass spectrometry (ICP-MS)
(Figure 6H), indicating that stimulation of lysosomal exocytosis
helps to excrete Cu from hepatocytes into biliary areas.
ATP7B Silencing Inhibits Apical Lysosomal Exocytosis,
Cu Excretion, and Polarization of Hepatic Cells
We then determined whether ATP7B is required for lysosome
exocytosis at the apical surface of hepatic cells. To this end, we
silenced ATP7B expression in polarized HepG2 cells (Figures
7A and 7B) and found that, in contrast to control cells, ATP7B-
deficient cells exhibited noCD63within canalicular domains (Fig-
ure7C, arrows). This finding suggests thatATP7Bpresence at the
lysosomesmight define their ability to undergo apical exocytosis.
Interestingly, ATP7Bablation also affected polarization of HepG2
cells, as we detected a reduction in the number of hepatocytes
making MDR1-positive canalicular cysts (Figures S4A, arrows,
and S4B) and a mistargeting of MDR1 to the basolateral surface
in silenced cells (Figures 7C, arrowheads, and S4A).
We also investigated the intracellular distribution of Cu in
ATP7B-deficient cells. We detected CS3 fluorescence within
the LAMP1-GFP-positive structures of control cells, whereas in
ATP7B-silenced cells, CS3 was hardly visible in LAMP1-GFP
spots (Figure 7D, arrows), indicating that lysosomes did not
receive Cu in the absence of ATP7B. Finally, we also foundDevelthat CS3 fluorescence in the canalicular area of ATP7B-deficient
HepG2 cells was lower than in control hepatocytes (Figure 7E,
arrows), whereas intracellular CS3 signal increased (Figures 7E
and 7F). Elevated intracellular Cu levels in ATP7B-silenced
HepG2 cells were also confirmed by ICP-MS (Figure 7G).
Taken together, these results indicate that ATP7B is involved
(1) in Cu import into lysosomes and (2) in apical exocytosis of
such lysosomes that allows elimination of excess Cu from the
cells and supports hepatocyte polarity.
Cu-Dependent Interaction with p62 Dynactin Subunit
Defines ATP7B Targeting to the Canalicular Surface of
Hepatic Cells
To understand the molecular mechanism through which ATP7B
targets lysosomes to the apical surface of hepatocytes, we
analyzed the publications on Cu-dependent protein interactions
of ATP7B. From this information, we found the interaction be-
tween ATP7B and the p62 subunit of dynactin (DNCT4) to be
particularly attractive from the trafficking standpoint (Lim et al.,
2006). Given that the minus ends of the microtubules are ori-
ented toward the canalicular domain of hepatocytes (Cohen
et al., 2004), the binding to p62 may allow ATP7B-containing
membranes to anchor the dynein motor and, therefore, be trans-
located to the biliary surface.
To test this hypothesis, we first immunoprecipitated endo-
genous p62 from either BCS- or CuSO4-treated HepG2 cells
and found significantly higher amounts of ATP7B in pull-downs
from the cells kept in high Cu (Figure 7H). Cu-dependent asso-
ciation of ATP7B with p62 was confirmed further using proximity
ligation assay (PLA) (D’Agostino et al., 2013). Figure 7I shows a
clear PLA signal, indicating close association between ATP7B
and p62 in cells that were exposed to CuSO4. Such PLA signal
was lacking in BCS-treated cells (Figure 7I), suggesting that
the effective interaction of ATP7B with p62 occurs only when
the intracellular Cu increases. We then analyzed the impact
of p62 silencing (Figure 7J) on Cu-dependent trafficking of
ATP7B. We found that p62 depletion did not affect ATP7B
transport from the Golgi to lysosomes upon increase in Cu con-
centration (Figure S4C). However, further clustering of ATP7B-
contaning lysosomes around the apical cyst and delivery of
ATP7B to the canalicular surface were seriously compromised
in p62-deficient HepG2 cells (Figure 7K, arrows). To further eval-
uate the impact of p62-ATP7B interaction on the lysosomal
exocytosis, we depleted p62 or ATP7B and measured the acti-
vity of lysosomal enzyme b-Gal within canalicular cysts of polar-
ized HepG2 cells stimulated with CuSO4. Both ATP7B-silenced
and p62-silenced cells exhibited significant reduction of enzyme
activities within the canalicular vacuoles (Figure 7L).
Notably, as it occurred in ATP7B-depleted cells, ablation of
p62 resulted in partial loss of polarity of HepG2 cells and partial
missorting of MDR1 from canalicular cysts (Figures 7K, arrow-
heads, S4D, and S4E). In contrast, the distribution of basolateral
markers such as E-cadherin and Na/K-ATPase remained intact
(Figure S4B) in silenced cells.
Taken together, these findings suggest (1) that the Cu-depen-
dent interaction between ATP7B and p62 is required for apical
exocytosis of ATP7B-positive lysosomes at the canalicular sur-
face of hepatocytes and (2) that this process contributes to the
polarization of HepG2 cells.opmental Cell 29, 686–700, June 23, 2014 ª2014 The Authors 693
Figure 6. Activation of Lysosomal Exocytosis Stimulates Cu Excretion from HepG2 Cells
(A) HepG2 cells were incubated with either 200 mMBCS or 200 mMCuSO4 for 2 hr loaded with CS3 for 15min before visualization at the confocal microscope. Cu-
associated CS3 signal was low in BCS-treated cells but significantly increased in Cu-loaded cells (see false color images of CS3 intensity in lower row).
(B) Quantification of the CS3 fluorescent intensity (mean ± SD; n = 15 fields) indicated its increase in CuSO4-treated cells.
(C) Cells were treated like in (A) and prepared for atomic adsorption spectroscopy (AAS) or inductively coupled plasma mass spectrometry (ICP-MS), which
revealed an increase in intracellular Cu concentration (mean ± SD; n = 4 experiments) in CuSO4-treated cells.
(D) HepG2 cells were infected with adeno-ATP7B-GFP, exposed to BCS, and observed in confocal microscope either directly or after 15 min or 2 hr incubation
with CuSO4. Insets show CS3 fluorescence within circular ATP7B lysosomes.
(E) Polarized HepG2-MDR1 cells were infected with HDAd-TFEB and then exposed to 200 mM CuSO4 for 8 hr and loaded with CS3.
(F) 3D plots show the intensity of the CS3 signal in the corresponding canalicular areas (dash line in D).
(G) Levels of CS3 fluorescence within canalicular cysts of HepG2 cells (mean ± SD; n = 100 cysts) increased in cells overexpressing TFEB.
(H) Polarized HepG2-MDR1 cells were infected with HDAs-TFEB and treated with CuSO4 as in (E). Afterward, canalicular cysts were opened with EDTA and
their content was analyzed for Cu using ICP-MS. Normalized Cu concentration (mean ± SD; n = 3 experiments) increased in the biliary cysts of cells over-
expressing TFEB.
The scale bars represent 7.5 mm (A) and 4 mm (D and E).
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ATP7B-Driven Lysosome Exocytosis in Cu HomeostasisActivation of Lysosomal Exocytosis Accelerates Cell
Surface Delivery of the Most Frequent Wilson-Disease-
Causing ATP7B Mutant
Finally, we determined whether activation of lysosomal exocy-
tosis could be utilized as a therapeutic strategy to contrast694 Developmental Cell 29, 686–700, June 23, 2014 ª2014 The AuthWilson disease (WD) pathogenesis. The most frequent ATP7B
mutant H1069Q (up to 50% in Caucasian population; Payne
et al., 1998), exhibits residual catalytic activity (van den Berghe
et al., 2009) but is retained within the endoplasmic reticulum
(ER), where it undergoes degradation (Payne et al., 1998; vanors
Figure 7. ATP7B Regulates Lysosomal Exocytosis and Cu Excretion through Interaction with p62
(A) Western blot reveals reduction in ATP7B expression in HepG2-MDR1 incubated with ATP7B-specific siRNAs.
(B) qRT-PCR indicates reduction of ATP7B mRNA levels (mean ± SD; n = 3 experiments) in ATP7B-silenced cells.
(C) Polarized control and ATP7B-silenced HepG2-MDR1 cells were exposed to 200 mMCuSO4 for 8 hr, fixed, and stained for CD63. Arrows indicate apical cysts
whereas arrowheads show MDR1 mistargeting from the canalicular area.
(D) Control and ATP7B-silenced HepG2 cells were transfected with LAMP1-GFP, exposed to CuSO4, and loaded with CS3. Arrows indicate LAMP1-positive
structures.
(legend continued on next page)
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ATP7B-Driven Lysosome Exocytosis in Cu Homeostasisden Berghe et al., 2009). Thus, correction of this mutant to the
regular functional compartment might be beneficial for the large
cohort of the WD patients. Interestingly, despite extensive re-
tention within the ER (Figures 8A and 8B, arrows), some
ATP7BH1069Q gets transported to the Golgi (empty arrows in Fig-
ures 8A and 8B) and further to LAMP1-positive structures (Fig-
ure 8A, solid arrows). Thus, we reasoned that acceleration of
lysosomal exocytosis might allow a more-efficient supply of re-
sidual ATP7BH1069Q to the cell surface, where it can transport
Cu out of the cell. To test this, TFEB-overexpressing CF7 cells
were infected with an adenovirus carrying ATP7BH1069Q and
exposed to CuSO4. Arrows in Figure 8A show that exocytosis-
prone lysosomes, which reside near the surface of CF7 cells
(Medina et al., 2011), received ATP7BH1069Q. This coincided
with a stronger immunogold labeling of the mutant protein at
the surface of CF7 cells compared to the parental HeLa line
(Figures 8B, arrowheads, and 8C). Correspondingly, a bio-
tinylation assay revealed a significant increase in the amount of
ATP7BH1069Q at the surface of CF7 cells (Figure 8D). Therefore,
activation of lysosomal exocytosis allowed recovery of addi-
tional quantities of ATP7BH1069Q at the cell surface.
To verify this conclusion in a liver-relevant system, polarized
HepG2 cells expressing ATP7BH1069Q were infected with
HDAd-TFEB and exposed to CuSO4 for 8 hr. Confocal micro-
scopy revealed that, in control cells, ATP7BH1069Q was hardly
detectable within the MRP2-positive canalicular cysts, whereas
overexpression of TFEB stimulated delivery of themutant ATP7B
toward the canalicular domain of hepatocytes (Figure 8E,
arrows). Therefore, activation of lysosomal exocytosis allows re-
covery of additional amounts of ATP7BH1069Q at the cell surface.
DISCUSSION
Our findings indicate that exposure of hepatocytes to increasing
Cu concentrations induces ATP7B trafficking from the TGN to
subset of lysosomes, where ATP7B imports Cu into the lyso-
somal lumen and where the metal can be transiently stored.
Further Cu increase over a threshold value (approximately
20 mM) induces the exocytosis of lysosomes containing ATP7B
with subsequent delivery of the Cu transporter to the apical
surface of hepatocytes and the release of Cu into the biliary
space. Importantly, ATP7B determines both the ability of the
lysosome to undergo exocytosis and also the apical/canalicular
direction of the exocytic process. Apparently, exocytosis is trig-(E) Control and ATP7B-silenced HepG2-MDR1 cells were treated with 200 mM C
vacuoles.
(F) Ratio between intracellular and canalicular CS3 fluorescence (mean ± SD; n =
(G) Cells were treated like in (E) and prepared for ICP-MS, which revealed an inc
ATP7B depletion.
(H) HepG2 cells were infected with adeno-ATP7B-GFP, exposed to BCS and or
Western blot reveals that similar amount of p62 pulls down higher amount of AT
(I) The cells were infected and treated like in (A) and processed for PLA analysis (se
and p62 was detectable as red spots (arrows) only in CuSO4-treated cells.
(J) Western blot and qRT-PCR indicate reduction of p62 at both protein and mR
(K) Control and p62-silenced polarized HepG2-MDR1 cells were exposed to CuSO
Empty arrowheads indicate MDR1 mistargeting from the canalicular area.
(L) Control, p62-silenced, or ATP7B-silenced HepG2 cells were exposed to CuSO
n = 3 experiments) in the canalicular cysts upon depletion of either p62 or ATP7B
The scale bars represent 4 mm (C–E), 3 mm (I), and 5.2 mm (K).
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which allows ATP7B to anchor lysosomes on microtubule high-
ways directed toward the apical pole of hepatocytes. In our
view, this sequence of events outlines the main mechanism,
which is utilized by hepatocytes to remove excess Cu from liver
and which is affected by ATP7B mutations in Wilson disease.
Some signs of this mechanism were uncovered more than 20
years ago when lysosomes were suggested to operate in Cu
homeostasis (Gross et al., 1989). Later, ATP7B was even de-
tected in late endosomes (Harada et al., 2000, 2005), and its
involvement in the secretion of some lysosomal enzymes into
bile was reported (Sugawara et al., 1995). Unfortunately, the
conclusive experiments that would directly demonstrate a role
of lysosomal exocytosis in ATP7B trafficking, molecular mecha-
nisms behind this process, and its coordination with Cu excre-
tion were not performed. Therefore, above findings remained
mostly neglected over the last decade. This happened mainly
because ATP7B trafficking and compartmentalization, which
constitutes the centerpiece of Cu homeostasis in liver, remained
poorly understood and highly controversial (La Fontaine and
Mercer, 2007; Polishchuk and Lutsenko, 2013). The major mys-
tery in the field was the nature of so-called ‘‘vesicles,’’ where
ATP7B resides in high-Cu conditions and how such vesicles
operate in Cu excretion.
In this study, identification of the ATP7B transport itinerary
allowed us to close these gaps and to complete the puzzle of
the mechanism at the basis of Cu excretion in hepatocytes.
Our initial finding revealed a subpopulation of lysosomes as
the main intermediate in ATP7B trafficking. We demonstrated
lysosomes to receive ATP7B directly from the TGN in response
to increasing Cu and to actively use this pump for Cu import.
This allowed us to assign the elusive ‘‘vesicular’’ ATP7B
compartment with identity of the lysosomes.
The lysosomal localization of ATP7B in high Cu conditions
raises several issues regarding the ATP7B-dependent mecha-
nisms of Cu homeostasis. The first is whether Cu is required in
the lysosome or it is merely sequestered there. Cu in lysosomes
can be utilized as a cofactor by housekeeping enzymes (acid
sphingomyelinase) (Qiu et al., 2003). Interestingly, another Cu
pump, ATP7A, supplies the metal in a similar way to tyrosinase
across the membrane of lysosome-related organelles melano-
somes (Setty et al., 2008). ATP7A was also found to transport
Cu into LAMP1/Rab7-positive phagosomes of macrophages,
where the metal has been hypothesized to kill engulfed bacteriauSO4 for 8 hr and loaded with CS3. Arrows show MDR1-positive canalicular
100 cells) increased in ATP7B-deficient cells.
rease in normalized Cu concentration (average ± SD; n = 4 experiments) upon
CuSO4, lysed, and subjected to immunoprecipitation with anti-p62 antibody.
P7B in CuSO4-treated cells.
e Experimental Procedures). PLA signal indicating close association of ATP7B
NA levels in HepG2-MDR1 cells incubated with p62-specific siRNAs.
4, fixed, and stained for endogenous ATP7B. Arrows indicate canalicular cysts.
4 for 8 hr. The chart shows decrease of normalized activity of b-Gal (mean ± SD;
.
ors
Figure 8. Activation of Lysosomal Exocytosis Improves Delivery of Most-Frequent WD-Causing ATP7BH1069Q Mutant to the Cell Surface
(A) Control HeLa cells and CF7 cells were infected with adeno-ATP7BH1069Q-GFP, incubated with 200 mM CuSO4 for 2 hr, and stained for LAMP1 and TGN 46.
Open and solid arrows show Golgi and lysosomes, respectively.
(B) Control HeLa and CF7 cells were treated as in (A), fixed, and processed for immunogold EM to reveal ATP7BH1069Q distribution. Although ATP7BH1069Q was
mistargeted to the ER (arrows), it can be detected also in theGolgi (empty arrow) and lysosomes (empty arrowheads). Filled arrowheads indicate higher amount of
ATP7BH1069Q at the surface of CF7 cells.
(C) Quantification revealed increase in the percentage of ATP7B-associated gold particles (average ± SD; n = 30 cells) at the plasma membrane in CF7 cells.
(legend continued on next page)
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ATP7B-Driven Lysosome Exocytosis in Cu Homeostasis(White et al., 2009). Thus, the ability to reach the lysosomal
compartment and to function there could be a common feature
of both Cu ATPases. Importantly, low pH in the lysosomes
does not inhibit metal-transporting activity of ATP7B but favors
it (Safaei et al., 2008).
The second issue is whether liver lysosomes may operate as
Cu storage compartments. Our data suggest that lysosomes
can uptake excessCu from the cytosol throughATP7B (Figure 6),
whereas the release of Cu in the opposite direction could occur
through the lysosome-targeted Cu channel CTR2 (van den
Berghe et al., 2007) when this metal is needed in the cytosol.
We found that, at the Cu concentrations below 20 mM, ATP7B
reaches the lysosomes from the TGN, but these lysosomes do
not undergo exocytosis unless Cu levels increase further. This
probably allows the ATP7B lysosomes to transiently store Cu,
when its concentration does not yet threat cell homeostasis.
Therefore, Cu fluxes to and from the lysosomes and, hence,
Cu storage in these organelles should be tightly regulated.
Indeed, yeast cells utilize vacuole (lysosome analog) for Cu
storage (Nevitt et al., 2012), indicating that this function of lyso-
somes is conserved in evolution.
The third issue is whether an ATP7B-positive subset of lyso-
somes resembles lysosome-related organelles (LROs), which
discharge their content in response to specific stimuli (Raposo
et al., 2007). This property may be required for rapid release of
Cu from the lysosome lumen into the bile in response to Cu
overload. However, we found that neither Rab27A nor VAMP7
nor synaptotagmin7 depletion affected exocytosis of ATP7B-
positive structures (Figure S5). Thus, in terms of exocytosis,
ATP7B-positive lysosomes do not resemble LROs,which require
Rab27A (Raposo et al., 2007). On the other hand, ATP7B-
positive lysosomes share only some common elements of the
exocytic molecular machinery (Ca2+ and MCOLN1) with com-
mon lysosomes, which need VAMP7 and synaptotagmin7 for
exocytosis. In our view, the lysosomes may require a specific
and unique asset of molecules for apical exocytosis in hepato-
cytes. ATP7B itself may be a part of such specific machinery,
as it is expressed almost exclusively in hepatic cells (Lutsenko
et al., 2007).
In this context, another significant finding of our study indi-
cates lysosomal exocytosis to operate for both ATP7B and Cu
delivery to the biliary surface of hepatocytes. Lysosomal exocy-
tosis plays a major role in several physiological processes such
as cellular immune response, bone resorption, and PM repair
(Andrews, 2000). Our in vitro and in vivo data suggest that stim-
ulation of lysosomal exocytosis increases both ATP7B and Cu in
biliary cysts. Thus, it turns out that exocytosis of the lysosomes
allows hepatocytes to expel sequestered Cu and to deliver
ATP7B to canalicular surface, where it might pump Cu directly
from the cytosol into the bile (Hubbard and Braiterman, 2008).
Our discovery of the ATP7B trafficking mechanism poses new
questions. The first question addresses the way in which Cu trig-
gers exocytosis of the lysosomes that receive ATP7B. We found(D) HeLa and CF7 cells were infected with adeno-ATP7BH1069Q-GFP and then p
CuSO4. Western blot revealed higher amount of ATP7B at the surface of CF7 ce
(E) Polarized HepG2 cells expressing ATP7BH1069Q-GFP were infected with HDA
marker MRP2. Arrows indicate canalicular cyst.
The scale bars represent 3.8 mm (A), 240 nm (B), and 6.5 mm (E).
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of lysosomal content at the biliary surface (Figures 7C and 7L). In
line with these observations, ATP7B-deficient rats exhibit signif-
icant decrease of lysosome enzyme activity in the bile (Sugawara
et al., 1995), presumably due to suppression of lysosomal exocy-
tosis in the absence of functional ATP7B. Thus, the presence of
ATP7B probably defines whether a given lysosome has to un-
dergo exocytosis in hepatocytes when Cu increases. Moreover,
ATP7B also determines the apical/canalicular direction of such
exocytosis. We found that the ability of ATP7B to drive exocytic
processes in response to Cu is likely governed by ATP7B’s inter-
action with the p62. p62 interacts with ATP7B in the presence of
high Cu (Lim et al., 2006; see also Figures 7H and 7I) and there-
fore, being in complex with dynactin and dynein motor, can
probably pull ATP7B-enriched lysosomes to the microtubule
minus ends, which are oriented toward the canalicular domain
of hepatocytes (Cohen et al., 2004). Indeed, we observed that
depletion of p62 does not allow ATP7B-containing lysosomes
to move toward the apical pole of HepG2 cells and to deliver
ATP7B to the canalicular surface, even in the presence of excess
Cu (see Figure 7). These findings are in line with previous studies
showing microtubule disruption to impair delivery of ATP7B to
the canalicular surface of HepG2 cells (Roelofsen et al., 2000).
Our observations also indicate that ATP7B-mediated lysosomal
exocytosis may contribute to polarization of hepatic cells (Fig-
ure S4), likely facilitating the delivery of specific proteins and
lipids to the apical membrane domain. Partial disorganization
of liver architecture and hepatic tumor development in ATP7B-
deficient mice (Huster et al., 2006) argues in favor of this
hypothesis.
The second question is whether and how the lysosome exo-
cytosis pathway may be utilized for therapeutic purposes. Stim-
ulation of lysosomal exocytosis via TFEB overexpression has
already been shown to promote cellular clearance in lysosomal
storage diseases (Medina et al., 2011). Here, we found that
transcriptional activation of lysosomal exocytosis allows partial
recovery of the proper subcellular localization of the most
frequent WD-causing mutant to the regular ATP7B functional
site. Given that this mutant possesses significant residual Cu-
transporting activity (van den Berghe et al., 2009), its rescue to
the correct location on the biliary surface of hepatocytes could
be beneficial for a large cohort of WD patients. On the other
hand, toxic Cu accumulation in lysosomes has been reported
during pathogenesis of choleostatic disorders (Gross et al.,
1989) and could be probably circumvented (contrasted) through
activation of the lysosome fusion with the cell membrane. In
addition, the well-known role of ATP7B in Wilson disease has
been recently expanded to its involvement in other pathologies
such as modulation of the Alzheimer’s disease phenotype and
anticancer drug resistance (Gupta and Lutsenko, 2009). Thus,
the ATP7B-dependent lysosomal exocytosis emerges as a
promising therapeutic target to combat WD and a number of
other disorders.repared for surface biotinylation directly or 2 hr after stimulation with 200 mM
lls.
d-TFEB, incubated with 200 mM CuSO4 for 8 hr, and stained with canalicular
ors
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Cell Culture and Transfection and Construction of Recombinant
Adenoviruses
HepG2, HepG2-MDR1, HeLa, and HeLa CF7 cells were grown in Dulbecco’s
modified Eagle’smedium supplemented with 10% fetal calf serum (decomple-
mented for HepG2), 2mM L-glutamine, penicillin, and streptomycin. For trans-
fection of plasmids, jetPEI TM-Hepatocyte (Polyplus transfection) and Trans IT
LT1 (TemaRicerca SRL) transfection reagents were used for HepG2 andHeLa,
respectively.
Trafficking Assay and Cu Treatment
To investigate localization of ATP7B at the different Cu load, cells were treated
with 200 mM Cu-chelating agent BCS and with different concentrations of
CuSO4. To compare trafficking of ATP7B with VSVG, cells were incubated
with BCS (overnight), then infected with VSV (Polishchuk et al., 2003), incu-
bated at 20C in the presence of BCS (to accumulate both proteins in the
Golgi), and finally warmed to 32C and treated with CuSO4 (to activate post-
Golgi transport of both proteins). Tannic acid (0.5%) was added in some exper-
iments during release of 20C block to inhibit fusion of post-Golgi transport
carriers with the PM (Polishchuk et al., 2004).
Mice and Treatment
Two-month-old males of Tcfeb-flox mouse (Settembre et al., 2013) were used.
TcFEB loxP/loxPmice that did not carry the albumin Crewere utilized as a con-
trol. To express ATP7B-GFP, mice were subjected to retro-orbital injection
with adeno-ATP7B-GFP 3 days before the experiment. To stimulate Cu excre-
tion from liver, both control and Tcfeb-flox mice received 0.125% CuSO4 in
water 4 hr before the animals were sacrificed (Gross et al., 1989). Liver tissue
was rapidly dissected from the mice, fixed, and processed for electron micro-
scopy, whereas bile was collected from gall bladder for b-Gal and b-Hex
assays. All experiments were approved by the Committee on Animal Care at
Baylor College of Medicine and conform to the legal mandates and federal
guidelines for the care and maintenance of laboratory animals.
Immunofluorescence and CS3 Labeling
Cells were fixed for 10 min with 4% paraformaldehyde in 0.2 M HEPES, per-
meabilized, labeled with primary and secondary antibodies, and examined
with a ZEISS LSM 700 or LSM 710 confocal microscope equipped with a
633 1.4 numerical aperture oil objective. For fluorescent Cu detection, cells
were incubated with 5 mM CS3 solution for 15 min at 37C. CS3 was excited
with 561 nm laser of LSM710, and its emission was collected from 565 to
650 nm. Colocalization module of ZEISS ZEN 2008 software was used to
measure colocalization of ATP7B with different intracellular markers. ATP7B
fluorescent signal inside canalicular domains and CS3 cytosolic and canalic-
ular surface signals were measured using ZEISS ZEN 2008 software and re-
ported in arbitrary units.
Immunoelectron Microscopy
For pre-embedding immunoelectron microscopy, cells were fixed, per-
meabilized, and labeled as described previously (Polishchuk et al., 2003).
For cryo-immunoelectron microscopy, specimens were fixed, frozen, and
cut using Leica EM FC7 ultramicrotome. Cryo sections were double labeled
for LAMP1 and GFP. EM images were acquired using a FEI Tecnai-12 electron
microscope. Morphometric analyses were performed using iTEM software
(Olympus SIS).
Statistical Analyses
Data are expressed as mean values ± SD. Statistical significance was
computed using the Student’s two-tail t test. A p value < 0.05 was considered
statistically significant. In all figures, *p < 0.05, **p < 0.01, and ***p < 0.001.
Additional Methods
Additional information on DNA constructs, adenoviruses, antibodies, immuno-
precipitation, surface biotinylation, PLA, quantitative RT-PCR (qRT-PCR),
RNAi, determination of b-Gal and b-Hex activities, atomic adsorption spec-
troscopy (AAS), and ICP-MS is provided in the Supplemental Experimental
Procedures.DevelSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2014.04.033.
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